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Ab   Antibody 
acLDL  Acetylated LDL 
AMPK   Adenosine monophosphate-activated protein kinase 
Apoe   Apolipoprotein E 
ATP   Adenosine-5'-triphosphate 
bFGF   Basic fibroblast growth factor 
BMDM  Bone marrow - derived monocytes / macrophages 
BMM   see BMDM 
BSA   Bovine serum albumin 
CAD   Coronary artery disease 
Calcein-AM  Calcein acetoxymethyl ester 
CCL2   Chemokine (C-C motif) ligand 2, see MCP-1 
CCL3   MIP-1α 
CCL4   MIP-1β 
CCL5   Chemokine (C-C motif) ligand 5, see RANTES 
CCR2   Chemokine (C-C motif) receptor 2, a receptor for MCP-1 
CD Cluster of diffentation – to identify cell surface molecules present 
on leukocytes  
CD31   see PECAM 
CD54   see ICAM 
CD74   Invariant chain of class II histocompatibility antigens 
CD106  see VCAM 
CD184  see CXCR4 
cDNA   Copy DNA 
CVD   Cardiovascular disease 
CXCR   Receptor for CXC chemokines  
CXCR4  Receptor for CXCL12 and MIF 
CXCR2  Receptor for CXC chemokines e.g. MIF and CXCL1 
CXCL1  see KC 
CXCL12  see SDF-1α 
Cy3, Cy7  Cyanine, used as fluorescent dyes 
DHE  Dihydroethidium 
ABBREVIATIONS 
VI 
DAPI   4',6-Diamidino-2-phenylindol 
DMSO   Dimethyl sulfoxide 
DNA    Desoxyribonucleic acid 
dPdt   Derivative of pressure increase and decay 
ECs   Endothelial cells 
ECFCs  Endothelial colony-forming cells 
ECM   Extracellular matrix 
ecNOS  Endothelial cell nitric oxide synthase 
EDTA   Ethylenediaminetetraacetic acid 
EPCs   Endothelial progenitor cells 
EOCs   Endothelial outgrowth cells 
EO-EPCs  Early outgrowth EPCs 
FACS   Fluorescent-activated cell sorting 
FCS    Fetal calf serum 
FGF   Fibroblast growth factor 
FITC   Fluorescein isothiocyanate 
FIZZ-1  Found in inflammatory zone, cysteine-rich secreted protein 
Flk-1   Fetal liver kinase 1, also known as KDR 
GAGs   Glycosaminoglycans 
GAPDH   Glyceraldehyde-3-phosphate dehydrogenase 
G-CSF   Granulocyte colony-stimulating factor  
GM-CSF   Granulocyte-macrophage colony-stimulating factor  
GTP   Guanosine 5'-triphosphate 
h   Hours 
HBSS   Hanks' balanced salt solution 
HH-buffer  Henderson-Hasselbalch buffer 
HIF   Hypoxia-inducible transcription factor 
ICAM Inter-cellular adhesion molecule, also known as CD54, 
expressed on endothelial cells 
IFN    Interferon 
IgG   Immunoglobulin G 
IL   Interleukin 
iNOS   Inducible nitric oxide synthase 
i.p.   Intraperitoneal 
ABBREVIATIONS 
VII 
i.v.   Intravenous 
KC   Keratinocyte-derived chemokine, also named CXCL1 
KDR Kinase insert domain receptor, also known as vascular 
endothelial growth factor receptor 2 
LAD   Left anterior descending artery 
LCM   L292 cell conditioned medium 
LDL   Low density lipoprotein 
LFA-1 Lymphocyte function-associated antigen 1, an integrin expressed 
on all T-cells, B-cells, macrophages and neutrophils mediating 
the recruitment to the site of infection 
LPS  Lipopolysaccharide 
LV  Left ventricle 
LVDP  Left ventricular developed pressure 
Ly6  Lymphocyte antigen 6 complex 
mAb    Monoclonal antibody 
Mac1 Macrophage-1 antigen, an integrin consisting of CD11b and 
CD18 
Mac2 Macrophage-2 antigen, used for macrophage staining 
MCP-1 Monocyte chemoattractant protein-1, also named CCL2, 
important mediator of monocyte recruitment to inflammatory sites 
M-CSF Macrophage colony-stimulating factor 
MHC    Major histocompatibility complex 
MI   Myocardial infarction 
MIF   Macrophage migration inhibitory factor 
min    Minute 
MIP   Macrophage inflammatory protein 
MMP Matrix metalloproteinase (that degrade components of the 
extracellular matrix) 
NO Nitric oxide, known as nitrogen monoxide 
O2   Molecular oxygen 
oxLDL  Oxidized low density lipoprotein 
pAb    Polyclonal antibody 
PAOD   Peripheral artery occlusive disease  
PAD    Peripheral artery disease 
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VIII 
PBMC  Peripheral blood mononuclear cells 
PBS    Phosphate-buffered saline 
PCR    Polymerase chain reaction 
PE   Phycoerythrin 
PECAM  Platelet/endothelial cell adhesion molecule 1, also named CD31 
PerCP  Peridinin – chlorophyll - protein complex 
PFA   Paraformaldehyde 
PGE2   Prostaglandin E2 
PIGF   Placental growth factor, abbr. also PGF 
PS   Phosphatidylserine 
RANTES  Regulated on activation normal T cell expressed and secreted 
rm   Recombinant murine 
RNA    Ribonucleotide acid 
SDF  Stromal cell-derived factor 
SEM    Standard error of the mean 
SMA   Smooth muscle actin 
SMCs   Smooth muscle cells 
TG   Trigyceride 
TGF   Tumor growth factor 
TNF   Tumor necrosis factor 
TSST-1  Toxic shock syndrome toxin - 1 
TTC   Triphenyl tetrazolium chloride 
VCAM Vascular cell adhesion molecule, also known as CD106, 
expressed on endothelial cells 
VE-cadherin  Vascular endothelial cadherin – adhesion molecule 
VEGF   Vascular endothelial growth factor 
VEGFR  Vascular endothelial growth factor receptor 
wt    Wild-type 
YM1 Also called T-lymphocyte-derived eosinophil chemotactic factor 
(ECF-L), marker of alternatively activated M2 macrophages 
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I INTRODUCTION 
 
I.1 Cardiovascular Diseases, Myocardial Infarction, and Peripheral Artery 
Disease 
Cardiovascular diseases (CVDs) comprise a class of disorders of the heart and blood 
vessels including coronary artery- (CAD), cerebrovascular and peripheral arterial 
disease (PAD). CVDs represent the number one cause of death and morbidity 
globally. In 2004, 17.1 million people died from CVDs, which represents 29% of 
deaths worldwide, with approximately 7.2 million related to CAD and 5.7 million to 
stroke. It is estimated that 27 million people in Western Europe and North America, 
10 million in the United States alone, suffer from PAD (Belch et al., 2003; Niiyama et 
al., 2009). The incidence of CVD-related mortality is growing rapidly due to an aging 
population, smoking, hypertension, high body mass index and rising prevalence of 
diabetes mellitus (Badheka et al., 2011; Dick et al., 2007). By 2030, it is expected 
that this number will have increased to a total of 23.6 million people (WHO, 2011).  
 
CVD is a manifestation of systemic atherosclerosis and CVD patients are often at 
high risk of developing ischemic distress (i.e. intermittent claudication and angina) 
stroke and cardiac death (Hirsch et al., 2006). The main cause of CVD is the 
narrowing of the blood vessel lumen by clogged fatty deposits (atherosclerotic 
plaque) and calcification of the vessel wall. These atherosclerotic and hardened 
arteries have lower conductance, and resulting reduced blood flow that will eventually 
lead to hypoxic tissue and subsequently, chronic pain and even stroke and limb 
amputation (Comerota, 2001).  
 
Treatment of CVDs is limited and often necessitates palliative interventions to relief 
malperfusion of the affected tissues and organs with for instance, medication, 
coronary artery bypass grafting or balloon angioplasty and stenting in CAD patients 
(Heil and Schaper, 2007).  
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I.2 Angiogenesis and Arteriogenesis, Two Forms of Vascularization 
The formation of a functional and integrated vascular network is a basic process in 
the growth and maintenance of tissue. Vascularization encompasses three major 
forms of blood vessel growth: vasculogenesis, angiogenesis and arteriogenesis. 
Vasculogenesis, de novo formation of vascular structures from mesenchymal 
angioblasts, is the earliest morphogenetic process of vascular development and 
takes place during early embryonic stages (Buschmann and Schaper, 1999; Risau 
and Flamme, 1995). Postnatal vasculogenesis mediated by endothelial progenitor 
cells (EPCs) derived from the bone marrow may occur as well (Asahara et al., 1999) 
(Simons and Ware, 2003), however the association of this process with adult 
neovascularization remains controversial. 
 
After birth, blood vessel development can be observed in two distinct mechanisms 
referred to as angiogenesis and arteriogenesis. Angiogenesis is the sprouting and 
tube formation from pre-existing blood vessels, but also from newly recruited EPCs, 
resulting in a higher capillary density. Arteriogenesis is the rapid proliferation of 
collateral arteries from pre-existing arterioles and is the only form of blood vessel 
growth process that can compensate for flow deficiencies caused by arterial 
occlusion.  
 
 
I.2.1 Angiogenesis 
Angiogenesis is the growth of blood vessels from pre-existing vasculature. It occurs 
throughout life and is an important component of different physiological and 
pathological conditions such as wound healing, fracture repair, and pregnancy 
(Conway et al., 2001). It is essential that angiogenesis is tightly regulated, combining 
angiogenic and angiostatic stimuli. However, if not properly controlled, it can lead to 
tumor growth and metastasis, rheumatic arthritis, and retinopathies (Buschmann and 
Schaper, 1999). The therapeutic value of angiogenesis has become a factor of great 
interest. Inhibiting or decreasing angiogenesis possess therapeutic potential in 
treating cancer and rheumatic arthritis, while stimulation of angiogenesis can be 
therapeutic in ischemic heart disease, peripheral arterial disease, and wound healing 
by increasing reperfusion of the tissue.  
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Mechanisms of Angiogenesis 
The cardiovascular system is the first organ system that develops in the embryo 
(Risau, 1997). The endothelial cell develops during embryonic development, from the 
pluripotent, mesodermal stem cell-derived hemangioblast. These precursors give rise 
to angioblasts and hematopoietic stem cells. While hematopoietic stem cells 
eventually differentiate into all cell types found in the circulating blood, angioblasts 
have the potential to differentiate into proliferative endothelial cells that will participate 
in vasculogenesis and thereafter in angiogenesis (Schmidt et al., 2007).  
 
 
 
Figure 1: Origin of the hemangioblast cells. During embryonic development, 
hemangioblasts are derived from mesodermal stem cells. They give rise to pluripotential 
hematopoietic stem cells that generate the blood cells, lymphocytes and angioblasts, which 
are the precursors of vascular endothelial cells. Figure taken from Gilbert et al. (Gilbert, 
2000).  
 
 
Two types of angiogenesis are known to occur both in utero and in adults: sprouting 
angiogenesis and intussusceptive angiogenesis (Burri and Tarek, 1990). Sprouting 
angiogenesis involves the growth of sprouts consisting of endothelial cells towards 
angiogenic growth factors, such as vascular endothelial growth factor (VEGF), which 
contributes to new blood vessels (Adair and Montani, 2010). 
 
Intussusceptive angiogenesis, also known as splitting angiogenesis, describes the 
extension of the vessel wall into the lumen causing a single vessel to split in two 
vessels (Burri and Tarek, 1990). Intussusceptive angiogenesis plays an important 
role in vascular development in embryos where growth is fast and resources are 
limited. But also mechanical stress related to enhanced blood flow can initiate 
intussusceptive growth in some regions with high blood flow in the adult (Djonov et 
al., 2002; Kurz et al., 2003). It mainly creates new vessels where vessels already 
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exist. In addition of building new vessel structures, it is relevant in the formation of 
vein and artery bifurcations as well as in the pruning of larger microvessels (Djonov 
et al., 2002).  
Angiogenesis depends on a large number of molecules including growth factors and 
their receptors, cell adhesion molecules, extracellular matrix molecules and 
proteolytic enzymes. Proliferation and migration of endothelial cells are key steps in 
angiogenesis. Intriguingly, basic molecules like adenosine, a nucleoside produced in 
all cells of the body by the dephosphorylation of ATP can trigger this process by its 
ability to enhance VEGF expression (Adair et al., 2005; Adair and Montani, 2010; 
Meininger et al., 1988).  
 
 
Angiogenesis in Hypoxic Conditions 
Development of the vasculature occurs where blood vessels have to match nutritive 
needs of the tissue including the skeletal muscle, the heart, and the brain. Oxygen 
plays a crucial role in controlling angiogenesis in these tissues. Hypoxic conditions 
stimulate vessel growth by activation of endothelial cells (i.e. proliferation and 
migration). The cellular response to hypoxia is mediated via up-regulation of hypoxia 
inducible transcription factors (HIFs), such as HIF-1α, HIF-1β, and HIF-2α. HIFs up-
regulate transcription of numerous genes, thereby affecting endothelial cell growth, 
smooth muscle cell recruitment, leukocyte attraction, etc. HIF-1 is the best 
characterized inducer of VEGF expression, the trigger for angiogenesis (Kimura et 
al., 2000). Most systems in the body are controlled by a negative feedback loop. In 
the case of angiogenesis, hypoxia induces the release of VEGF, which in turn 
stimulates blood vessel growth. The newly formed capillaries can increase the supply 
of oxygen, leading to a reduction of VEGF secretion and in turn stop further 
development of the vasculature (Adair, 2005; Adair et al., 1990; Adair and Montani, 
2010).  
 
The VEGF family of proteins, including VEGF-A, -B, -C, -D and PIGF, are strong 
signalling proteins involved in vasculogenesis and angiogenesis by binding and 
thereby activating their receptors (VEGF-R 1-3) (Li et al., 2006). After VEGF is 
secreted into the extracellular space it can control the onset, extent and duration of 
angiogenesis via binding to its cognate VEGFR´s. VEGF is responsible for increased 
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vascular permeability, inflicted through redistribution of intercellular adhesion 
molecules (Gale and Yancopoulos, 1999), and is followed by extravasation of plasma 
proteins that serve as scaffold for activated endothelial cells to migrate on (Ferrara et 
al., 2003). Although permeability supports angiogenesis, excessive vascular leakage 
can end in circulatory collapse, intracranial hypertension, metastasis or blindness 
(Carmeliet, 2000; Conway et al., 2001). Therefore permeability is tightly regulated by 
for instance the natural anti-permeability factor glycoprotein angiopoietin-1 
(Carmeliet, 2000).  
 
Angiogenesis also requires degradation of vascular basement membrane and 
remodeling of extracellular matrix in order to allow endothelial cells to migrate and 
invade into the surrounding tissue (Rundhaug, 2005). Matrix metalloproteinases 
(MMPs), a family of zinc endopeptidases participate in this remodeling of the 
basement membrane by facilitating proteolytically degradation of various components 
of the extracellular matrix (ECM), such as laminin and fibronection. Via this ECM 
remodelling, MMPs also regulate the release of ECM-associated growth factors such 
as VEGF, that in turn animates  the communication of endothelial cells to each other 
allowing them to migrate (Noël et al., 2011). To form a vessel the newly formed 
endothelial sprout needs to develop a capillary lumen. This is caused by thinning of 
endothelial cells and fusion of endothelial strands to increase in length and diameter. 
After forming a new vessel, endothelial cells stop to migrate, become quiescent and 
survive for years (Carmeliet, 2000).  
 
In addition to endothelial cells, mural cells are linked to the formation of new vessels 
(Crocker et al., 1970). Smooth muscle cells have been identified as the mural cells of 
arteries, arterioles and veins, whereas pericytes (multipotent mesenchymal-like cells) 
have been identified as mural cells of capillaries and venules (Rhodin, 1968). During 
development and angiogenesis, mural cells play an important role in vascular 
development (Hughes, 2004). Endothelial cells and pericytes communicate with each 
other to secure recruitment of pericytes to the external mesenchyme to form small 
blood vessels (Lu and Sood, 2008). This association between endothelial cells and 
pericytes stabilizes the newly formed endothelial tubes, promote endothelial survival 
(Benjamin et al., 1998) and inhibit endothelial proliferation and migration (Hirschi et 
al., 1998; Sato and Rifkin, 1989). Lack of these pericytes will lead to endothelial 
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hyperplasia and abnormal vascular remodeling (Hellstrom et al., 2001).  
 
 
 
 
Figure 2: Pericyte wrapped around the capillary. Taken from: (Dorland´s Medical 
Dictionary for Health Consumers, 2007).  
 
 
Murine Myocardial Infarction Model, a Model of Angiogenesis 
Myocardial infarction is an ischemic heart disease and is caused by interruption of 
the blood flow to the cardiac tissue. This can be caused by thrombotic occlusion of 
atherosclerotic coronary arteries. The resulting ischemia induces necrosis of the 
myocardium along with free radical generation, initiation of the complement cascade, 
and activation of nuclear factor-κB and Toll-like receptor-mediated signalling 
pathways (Frangogiannis et al., 2002). These events are accompanied by chemokine 
and cytokine synthesis, which modulate the inflammatory response. This process 
ultimately results in replacement of dead cardiomyocytes with collagen-based scar 
tissue and is important in myocardial healing (Frangogiannis and Entman, 2005; 
Frangogiannis et al., 2002; Weber, 2007). Leukocytes migrate into the infarcted 
myocardium followed by activation of proteases and extensive degradation of cardiac 
ECM. One of the major therapeutic purposes of cardiology is to create strategies to 
minimize myocardial necrosis and improve cardiac repair and function after infarction. 
The mouse myocardial infarction model mimics the acute infarcted situation in 
patients and can be used to study the disease process and test new therapeutic 
interventions. 
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Figure 3: The mouse model of myocardial infarction. To induce a myocardial infarction, 
the left anterior descending coronary is ligated, which deprives the cardiomyocytes of 
nutrients and oxygen supply. Figure taken from (Winslow and Kibiuk, 2001).  
 
 
The Role of Endothelial Progenitor Cells  
In 1997, Asahara et al. first described the isolation of putative endothelial progenitor 
cells from the peripheral blood. They isolated bone marrow-derived cells that 
expressed CD34 and VEGFR-2 (vascular endothelial growth factor receptor-2) and 
cultured them on fibronectin-coated plates. These cells then differentiate into cells 
with phenotypic features of endothelial cells (CD31+, E-selectin+, ecNOS+, uptake of 
oxidized Low Density Lipoprotein (ox-LDL)) and angiogenic potential (Asahara et al., 
1997).  
 
Some years later, Peichev et al. defined circulating EPCs as cells with surface 
markers including CD34, CD133 (originally named AC133), and the vascular 
endothelial growth factor receptor-2 (VEGFR2, alias Flk-1 or kinase insert domain 
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receptor KDR in murine and humans, respectively). During culturing, these cells lost 
their early hematopoietic stem-cell marker CD133, but gained further endothelial 
markers (i.e. VE-cadherin) (Peichev et al., 2000).  
 
In vitro, two types of endothelial progenitor cells derived from CD34-positive 
mononuclear cells have been described: early and late outgrowth EPCs (EOCs), also 
called endothelial colony-forming cells (ECFCs). Both share common characteristics 
like the expression of CD14, CD31, lectin binding, and ox-LDL uptake, but they have 
also a distinct morphology, proliferative potential, and vascular tube formation 
capacity. In contrast to late EPCs, early EPCs do not proliferate but express 
haematopoietic markers (Ingram, 2004; Rehman et al., 2003). Since early EPCs do 
not show typical endothelial characteristics in vitro and they only increase 
neovascularization in an indirect way in vivo, some researchers have named them 
angiogenic cells (Rehman et al., 2003; Yoder et al., 2007). The early EPCs are 
currently being linked to angiogenic cells or macrophages. Raemer et al. described 
that adherent EPCs derived from blood mononuclear cells demonstrated antigen-
presenting capacity and co-stimulated T-cells similar to monocytes, but much more 
efficiently than human vascular endothelial cells (Raemer et al., 2009). Another study 
challenges the presence of endothelial cell markers in early outgrowth EPCs. It is 
considered that during cell culturing, platelet-derived microparticles are taken up by 
mononuclear cells, providing them with “endothelial characteristics” (von Willebrand 
factor, CD31, lectin-binding) and angiogenic properties (Prokopi et al., 2009).  
 
Only a small number of circulating CD34+ mononuclear cells in culture gives rise to 
late EPCs. These late EPCs are thought to be the true endothelial progenitor cells 
contributing more directly to neovascularization by providing new endothelial cells 
(ECs) to the vessel lining in vivo (Ingram, 2004; Rehman et al., 2003; Yoon, 2005).  
 
 
Endothelial Progenitor Cells in Angiogenesis and Vascular Repair  
Although no clear definition of EPCs exists, they are no longer regarded real 
endothelial progenitors. Nonetheless, there is no question about their potential to 
enhance vascular repair and angiogenesis. 
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EPCs secrete pro-angiogenic factors such as VEGF, granulocyte colony-stimulating 
factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Rehman et al., 2003). Both, early and late EPCs secrete pro-inflammatory cytokines, 
whereby the early EPCs release thrombo-inflammatory mediators such as tissue 
factor (TF) and the late EPCs release chemokines such as MCP-1 (monocyte 
chemoattractant protein-1). EPCs can also facilitate angiogenesis by secretion of 
angiogenic factors like cytokines and growth factors as well as matrix-degrading 
enzymes comparable with monocytes. These “monocytic EPCs” arrive prior to 
occurring angiogenesis and stimulate the formation of new vessels (Krenning et al., 
2009). All EPCs express pro-inflammatory factors and adhesion molecules linking 
them to atherosclerosis as well (Zhang et al., 2009). 
 
A therapeutic potential of EPCs has been suggested as they can improve vascular 
repair (Hristov and Weber, 2008). After wire injury in mouse carotid arteries, bone 
marrow-derived EPCs were detected to adhere to the injured vessel wall and were 
correlated with increased re-endothelialization and reduced neointima formation 
(Pearson, 2010). Treatment with statin, a drug applied normally to lower cholesterol 
levels, boosted the amount of circulating EPCs and adherence of bone marrow-
derived cells (Werner, 2002) showing therapeutic potential. Comparable, continual 
injection of bone marrow-derived progenitor cells from young non-atherosclerotic 
Apoe-/- (apolipoprotein E) mice in Apoe knockouts fed a high-fat diet (to induce 
atherosclerosis) prevented atherosclerosis progression in recipients (Rauscher, 
2003). On the other hand, George et al. showed that injection of EPCs and bone 
marrow-derived cells resulted in an increase in atherosclerotic plaque size and 
increased lesion formation, while the injection of EPCs even correlated with plaque 
destability (George, 2005). These controversial findings are probably due to the 
diversity of the cell population used (see previous paragraph), even though they are 
all called EPCs. 
 
 
I.2.2 Arteriogenesis 
Arteriogenesis is another type of vascular growth and is characterized by rapid 
proliferation and expansion of pre-existing collaterals. These microvascular vessels 
are thin-walled and compose an endothelial lining, an internal elastic lamina, and one 
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or two layers of smooth muscle cells (Longland, 1953). Blood vessels can adapt to 
changing blood flow conditions. Arteries can enlarge during chronically enhanced 
blood flow and degenerate when not constantly perfused, or enlarge the thickness of 
the vessel wall under high blood pressure (Kamiya and Togawa, 1980). These 
collateral vessels are able to substantially increase their lumen by five- to eight-fold 
(Scholz et al., 2000) by growing so as to provide increased perfusion to the ischemic 
regions.  
 
The obstructed region of an artery in which bypassing collaterals will grow, is 
normally more proximal to the hypoxic zone, and therefore its growth is independent 
of hypoxia (Heil and Schaper, 2007). In case of stenosis of a major artery, a pressure 
gradient between the high-pressure pre-occluded area and the low-pressure post-
occluded area develops. This pressure difference leads to enhanced blood flow 
velocity and hence increased shear stress in the interconnecting (collateral) vessels. 
Mechanical forces caused by this drastically altered blood flow situation are 
considered driving the induction of collateral growth and remodeling (Unthank et al., 
1996). 
 
Increased shear stress leads to an upregulation of distinct processes in collateral 
arteries and therefore activation of the endothelium, which is a first sign in the 
development of these vessels (Schaper et al., 1976). The activated endothelial cells 
upregulate cell adhesion molecules (ICAM, VCAM) and cytokines such as MCP-1 
(monocyte chemoattractant protein-1) (Chappell et al., 1998). The enhanced 
expression of the endothelium-derived chemokine MCP-1 specifically attracts blood 
monocytes to adhere and to invade the collaterals (Springer, 1994). After the 
differentiation into macrophages, they secrete a cocktail of factors that are beneficial 
for collateral artery growth. The secretion of proteases such as the MMPs, which in 
turn degrade extracellular structures like the elastic lamina, can trigger the 
proliferation and migration of smooth muscle cells. Even though only a small number 
of extra endothelial cells is required in the growth of collateral arteries, several layers 
of smooth muscle cells have to be formed during the development into a larger 
vessel. The increase of smooth muscle cells leads to a re-arrangement of the cell 
layers in the vessel wall (Heil and Schaper, 2007). 
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Stages of Arteriogenesis 
The process of arteriogenesis can be divided in four different stages with distinctive 
morphological and molecular markers, these are: initiation, proliferation, 
synthesis/migration, and maturation (Scholz et al., 2000).  
 
The initial phase starts minutes after vessel occlusion, at which increased shear 
stress leads to activation of endothelial cells and, subsequently induces and/or up-
regulates intercellular and vascular adhesion molecules. Approximately 12 hours 
after endothelial activation, monocytes adhere to the endothelium, migrate into the 
collateral tissue and secrete proteases that digest the elastic lamina (van Royen et 
al., 2009). The phase of proliferation begins 1-3 days after arterial occlusion. During 
this phase a maximal wave of mitosis of the endothelial cells, smooth muscles cells 
and fibroblasts is apparent. 3-14 days after occlusion, the most significant growth of 
the collaterals was found and is considered the synthetic/growth phase. While the 
mitotic activity in smooth muscles cells decreases over time, the synthetic and 
proteolytic activity rises, leading to a higher production of ECM (i.e. collagen and 
elastin), which in turn produces a new internal elastic lamina (Buschmann and 
Schaper, 1999). The maturation phase starts about two weeks after the occlusion 
and is characterized by low proliferation, migration, and proteolytic activity. Most of 
the “synthetic” smooth muscle cells restore a physiological “contractile” phenotype at 
this stage.  
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Figure 4: The mechanism of collateral artery growth. (A) In physiological conditions, with 
equal pressure over the pre-existing collateral arteries. (B) After arterial occlusion, a drop in 
pressure leads to a pressure gradient between pre-occlusive and post-occlusive area and 
lower oxygen saturation more distally (purple-blue color), while the proximal pressure and 
oxygen saturation stays normal (red color). This pressure gradient increases shear stress in 
these arterioles, the initial force for arteriogenesis. (C) Activated endothelium increases 
expression of adhesion molecules to attract circulating monocytes, which then transmigrate 
into the perivascular tissue. Perivascular macrophages secrete growth factors and cytokines 
that attract more monocytes and stimulate the proliferation of endothelial cells and smooth 
muscle cells. After adequate development of the collateral arteries the distal perfusion is 
restored, providing sufficient oxygen to the distal tissue. Figure taken from (Schirmer et al., 
2008).  
 
 
The Role of Monocytes/Macrophages in Arteriogenesis 
Monocytes are part of the circulating leukocytes that are derived from hematopoietic 
stem cells of the bone marrow. Monocytes continually migrate through the vessel wall 
into the tissue, where they differentiate into macrophages. In response to an 
inflammatory signal, the number of monocytes increases. Both monocytes and 
macrophages are phagocytic cells, ingesting and killing bacteria, pathogens, dead 
cells and cell debris. Since most of the infections with microorganisms occur in the 
tissue, macrophages exert primarily this protective role. Macrophages orchestrate 
immune, homeostatic, and inflammatory responses, involving the induction of 
inflammation, and the secretion of signalling proteins to activate further immune cells 
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and their recruitment to sites of inflammation (Murphy et al., 2007b). Overall, 
monocytes and macrophages have an eminent role in angiogenesis, arteriogenesis, 
and many chemokines/chemokine receptors induce their recruitment.  
 
The adhesion of circulating monocytes to the endothelium of collateral arteries was 
first observed by Jutta Schaper et al. (Schaper et al., 1976) indicating their important 
role in collateral vessel formation. A few years later Heil et al. demonstrated the 
functional link between monocyte concentration in peripheral blood and the 
improvement of arteriogenesis. 
 
 
 
Figure 5: Monocytes adhere to the inner vascular surface (Schaper et al., 1976). 
 
 
In a model of acute femoral artery ligation, it was observed that the pharmacological 
increase of the content of blood monocytes correlated with collateral conductance 
and number of collateral arteries and therefore, was regarded to accelerate 
arteriogenesis. On the other hand, depletion of monocytes almost abolishes the 
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growth of collateral arteries (Heil et al., 2002). During arteriogenesis, monocytes 
adhere to the vascular vessel wall at time points before maximal proliferation is 
observed for the collaterals. These monocytic cells produce large amounts of 
degrading enzymes, survival factors, growth factors and cytokines such as basic 
fibroblast growth factor (bFGF), TNF-α and VEGF, and are likely essential for 
stimulating endothelial and smooth muscle cell adaptation (Arras et al., 1998; Iijima et 
al., 1993; Sunderkotter et al., 1994). The up-regulation of survival factors such as 
granulocyte macrophage colony-stimulating factor (GM-CSF) keeps the environment 
optimal for a stable function of monocytes (Buschmann and Schaper, 1999). These, 
conversely, produce even more growth factors, such as transforming growth factor 
beta (TGF-β). The chemokine system contributes not only to angiogenesis in 
myocardial infarction, but also to the process of arteriogenesis after hindlimb 
ischemia by directly acting on inflammatory cells and vascular cell types as well. 
Transcriptional profiling of the adductor muscle in the hindlimb after femoral artery 
ligation showed an increase in the expression pattern of CC chemokines such as 
MCP-1 as well as CXC chemokines such as MIP-2 (murine macrophage 
inflammatory protein-2) (Lee et al., 2004).  
 
MCP-1 is the most extensively studied chemokine in the context of arteriogenesis 
(Heil and Schaper, 2005). As its name indicates, MCP-1 attracts monocytes to 
collateral endothelium. Increased fluid shear stress elevates MCP-1 secretion in 
cultured human endothelial cells, and has been shown to induce monocyte adhesion 
in vitro (Shyy et al., 1994). Local administration of MCP-1 via an osmotic minipump 
increased the density of collateral arteries after femoral artery ligation in rabbits and 
enhanced the collateral conductance, reaching values comparable to non-operated 
rabbits already after 7 days after femoral artery ligation. An increase in monocyte 
accumulation in the wall of collateral arteries was also observed in these animals 
revealing that chemoattractants recruit monocytes from the circulation to sites of 
activated collaterals (Ito et al., 1997b). MCP-1 exerts its function by binding to its 
receptor CCR2. In ischemia hindlimb studies using mice deficient in CCR2 
documented less blood flow recovery compared to wild-type mice and a smaller 
increase in collateral vessel diameters. Furthermore, the number of invaded 
macrophages in the perivascular space of the arteries of CCR2-/- was drastically 
diminished as compared with wild type (wt) - mice (Heil, 2004). On the contrary, Tang 
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et al. showed normal revascularization of CCR2-/- knockout mice in response to 
hindlimb ischemia. These CCR2-deficient mice exhibit normal blood flow recovery 
and arteriogenesis as well as normal monocyte and macrophage recruitment to the 
thigh (Tang et al., 2004). 
 
Another chemokine receptor, CXCR3 has also been associated with arteriogenesis, 
contributing to leukocyte recruitment and infiltration into an ischemic area. CXCR3-
deficient mice demonstrated a decrease in collateral artery formation and impaired 
restoration of perfusion after femoral artery occlusion. Interestingly, injection of bone 
marrow-derived mononuclear cells from wt-mice, but not from CXCR3-/- mice, 
restored the neovascularisation reaction and collateral artery density in the mutants, 
suggesting that the expression of CXCR3 in bone marrow-derived cells is necessary 
for arteriogenesis (Waeckel, 2005).  
 
Besides MCP-1 and CXCR3, intergrins present on monocytes and the intercellular 
and vascular cell adhesion molecules (ICAM, VCAM) on endothelial cells have been 
regarded essential in mediating adhesion of monocytes to the endothelium. Integrins 
are a family of cell surface receptors consisting of two subunits: a variable α-chain 
and a non-variable β-chain (Giancotti and Ruoslahti, 1999). Integrins signal across 
the plasma membrane in two directions. This so called inside-out (intracellular to 
extracellular) and outside-in (extracellular to intracellular) interaction is crucial for 
maintaining normal cell function (Qin et al., 2004). Integrins mediate sensing and 
response of cells to its environment, including other cells and ECM, as well as cell 
functions including movement, growth and survival (Giancotti and Ruoslahti, 1999; 
Hynes, 1987). Interaction of ICAM-1 on endothelial cells with integrin Mac-1 on 
monocytes facilitates invasion of monocytes into the vessel wall and accumulation in 
the perivascular space of growing collateral arteries (Scholz et al., 2000).  
 
Furthermore, growth factors such as VEGF are also involved in monocyte activation 
by stimulating the expression of leukocyte-specific integrins LFA-1 (lymphocyte 
function-associated antigen 1) and Mac-1. This, in turn, promotes the adhesion of 
monocytes to human endothelial cells and transmigration through an endothelial 
monolayer in vitro (Heil et al., 2000).  
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Hindlimb Ischemia Model, a Model of Arteriogenesis 
To treat patients suffering from ischemic vascular diseases, therapeutic strategies for 
symptomatic relief are limited. There is an urgent need to develop new strategies for 
treating peripheral artery disease (PAD). To compensate for perfusion deficits, 
introduction of collateral growth could be a good therapeutic approach. During the 
last years, numerous treatments have been suggested either with stimulatory 
substances or different types of cells. Endovascular or surgical interventions can be 
useful for a handful of people, but long-term indications are often disappointing. 
Arteriogenesis is so far the most effective form of vascular growth for the survival of 
the ischemic limbs and organs such as the brain and the heart. The murine hindlimb 
ischemia model is a complex model of collateral artery formation, which represents 
PAD, and is useful for testing new therapeutic interventions. 
 
Many studies have used the hindlimb ischemia model in different animals to describe 
several factors that influence arteriogenesis. The tissue response to ischemia in the 
hindlimb differs in distinct regions of the leg. After severe ischemic injury, necrosis 
occurs in the muscle below the knee followed by an acute inflammatory process with 
angiogenesis and muscle regeneration. On the contrary, arteriogenesis predominates 
proximal to the ischemic region (Scholz et al., 2002).  
 
 
 
 
 
 
 
 
 
 
                                                                         
Figure 6: Anatomy of the right mouse hindlimb vasculature. The N. Femoralis has been 
dissected for a better visualization (b). Scale bars, 2 mm. (Limbourg et al., 2009)  
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I.2.3 Angiogenesis vs. Arteriogenesis 
Both forms of vessel growth, angiogenesis and arteriogenesis, can be monitored 
after experimental occlusion of a peripheral or coronary artery, but they differ from 
one another in mechanism of induction, localization, and contribution of growth 
factors and circulating cells. Angiogenesis is induced by hypoxia and thus occurring 
in the ischemic region distal to the occlusion site. Importantly, arteriogenesis, 
independent of the presence of hypoxia, is induced by inflammation and enhanced 
shear stress due to increased collateral blood flow. A study in rabbits demonstrated 
that collateral arteries developed in non-ischemic regions without an activation of 
hypoxia-induced gene transcription and no rise in ischemic markers such as 
adenosine diphosphate, adenosine monophosphate or lactate, whereas 
angiogenesis occured in regions of profound ischemia (Ito et al., 1997a). 
 
Although angiogenesis and arteriogenesis are dependent on growth factors in 
general, the involved growth factors and chemokines are different in each process. 
Angiogenesis can be largely explained by the action of the growth factor VEGF. 
Neufeld et al. reviewed that VEGF is one of the most effective inducers and key 
regulators of angiogenesis, and its expression is potentiated in response to hypoxia 
(Neufeld et al., 1999). Furthermore, VEGF increases the permeabilization of blood 
vessels and stimulates vascular endothelial cell proliferation, induces macrophage 
migration, and inhibits apoptosis. These effects of VEGF are mediated by binding to 
its high-affinity receptors VEGFR1 and VEGFR2 (murine Flt-1 and Flk-1) expressed 
on endothelial cells (Neufeld et al., 1999). VEGF is only mitogenic for endothelial 
cells, but for the growth of collaterals, proliferation of both endothelial cells and 
smooth muscle cells are required. Neither the increased levels of VEGF nor the 
expression of the hypoxia-inducible genes were associated with arteriogenesis 
(Deindl et al., 2001).  
 
In case of arteriogenesis, remodeling and growth of thin-layered pre-existing 
collateral arteries sustained by growth factors and cytokines produced from 
circulating cells are essential, whereas in angiogenesis this remodeling process does 
not take place and it cannot adapt to changes in physiological demands of blood 
supply (Buschmann and Schaper, 1999). Examples of such growth factors and 
chemokines reported to be involved in angiogenesis are TGF-α, a-FGF and VEGF 
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inducing the proliferation of endothelial cells. In arteriogenesis, CCL2 is known as the 
most potent arteriogenic peptide; TGF-β and GM-CSF were shown to play an 
important role, also inducing the proliferation of smooth muscle cells (van Royen et 
al., 2001). Further differences between angiogenesis and arteriogenesis exist in the 
role of the participating cells. The accumulation of monocytes has a determinant role 
in arteriogenesis, but not in angiogenesis, which is more dependent on lymphocytes. 
 
 
 
Figure 7: Two forms of vessel growth, angiogenesis and arteriogenesis. This figure 
summerizes the differences in the underlying inducers, results and the involved factors that 
are mentioned in the text. Furthermore, it shows the overlap between angiogenesis and 
arteriogenesis. Figure combined from (Buschmann and Schaper, 1999; van Royen et al., 
2001).  
 
 
I.3 Cytokines and Chemokines 
Cytokines are small cell-signalling proteins (about 10 - 25kDa) that are secreted by 
numerous cells, normally in response to an activating stimulus. They elicit their 
activity through binding to specific receptors. Cytokines can be divided into at least 
two main groups dependent on their structure: the hematopoietin group, which 
includes growth hormones and many interleukins and the TNF group (Murphy et al., 
2007a) . 
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Among the cytokines released by tissues are members of a family of chemoattractant 
cytokines known as chemokines (chemotactic cytokines). The chemokine super- 
family exists of approximately 50 structurally related small molecular weight proteins 
of 8-10 kDa (Reape and Groot, 1999). They are secreted and responsible for 
leukocyte activation and migration (Charo and Ransohoff, 2006). Chemokines can be 
classified into four subfamilies according to their structure and function (CC, CXC, 
CX3C, and C chemokines); where C is a cysteine and X any amino-acid residue 
(Bazan et al., 1997). The largest subfamily consists of CC chemokines, where the 
first two of the four cysteine residues are adjacent to each other. CC chemokines 
attract mononuclear cells to sites of chronic inflammation. Monocyte chemoattractant 
protein (MCP-1, CCL2) is the most characterized CC chemokine (Charo and 
Ransohoff, 2006).  
 
A second subfamily, named CXC chemokines has a single amino acid residue 
interconnected between the first two cysteine residues. Some CXC chemokines, 
such as interleukin-8 (IL8, CXCL8) contribute to attraction of neutrophils to sites of 
inflamed tissue, whereas CXCL12/SDF-1 and CXCL1/KC are chemoattractants for T-
cells, monocoytes and neutrophils. The CX3C family consist of only one member, 
fractalkine (CX3CL1), where the N-terminal cysteines are separated by three amino 
acids. The soluble CX3C chemokine serves as a strong chemoattractant for T cells 
and monocytes, and the cell-surface-bound protein that is induced on activated 
primary endothelial cells, promotes strong adhesion of those leukocytes (Bazan et 
al., 1997). The fourth subgroup is the T-cell attracting C chemokine lymphotactin 
(XCL1), in which two out of the four cysteines are missing (Moser and Willimann, 
2004). 
 
Chemokines exert their biological activity though high-affinity interactions with its 
complement of chemokine surface receptors; CC chemokines bind to CC chemokine 
receptors, CXC chemokines to CXC receptors and so forth. These receptors, 
expressed on different cell types, are seven-transmembrane proteins that signal 
through coupled G proteins. Upon interaction with their specific chemokine ligands, 
the receptor activates signal transduction cascades that activate phosphatidyl-
inositol-3-kinases and triggers influx of intracellular Ca2+. Besides this ligand-receptor 
interplay, chemokines interact with low-affinity with proteoglycans consisting of a 
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protein core, to which glycosaminoglycan (GAG) chains are attached. The GAGs, 
which are expressed in several forms throughout the body especially on the 
endothelial cell surface, represent a heterogeneous polysaccharide family (Middleton, 
2002). This chemokine-GAG interaction enables the retention of chemokine to the 
surface of cells, thus creating a high local concentration gradient of chemokines that 
is needed for cell activation including leukocyte recruitment and migration throughout 
the tissue (Patel et al., 2001; Proudfoot, 2006). 
 
 
I.3.1 Receptor / Ligand Interactions in Monocyte Recruitment 
Chemokines and their cognate receptors play a pivotal role in directing the movement 
of mononuclear cells throughout the body (Charo and Ransohoff, 2006). Chemokine 
receptors are able to regulate inflammation and immunity by recruiting monocytes, 
neutrophils, and lymphocytes to the site of inflammation and vascular injury (Charo, 
2004; Charo and Ransohoff, 2006). The recruitment of activated leukocytes to sites 
of infection and the migration of leukocytes out of the blood vessel into the tissue is a 
multi-step process mediated by cell-adhesion molecules. These molecules can be 
induced on the surface of the endothelium of blood vessels. Three families of 
adhesion molecules play an important role in leukocyte migration, homing, and cell-
cell interactions: selectins, intercellular adhesion molecules and integrins.  
 
The selectins are single-chain transmembrane glycoproteins that can be grouped into 
E-selectin on endothelial cells, P-selectin on platelets and endothelial cells, and L-
selectin on leukocytes. After the endothelium gets activated, selectins are induced 
allowing monocytes and neutrophils to adhere reversibly to the vessel wall resulting 
in rolling of circulating leukocytes over the endothelial surface (Frangogiannis et al., 
2002).  
 
For transvascular migration, a stronger interaction of rolling leukocytes and 
endothelium is needed. Inflammatory cytokines are able to induce the expression of 
intercellular adhesion molecules (ICAMs) on the endothelium. Heterodimeric 
interactions of ICAM with integrin family members on leukocytes (e.g. LFA-1) 
facilitate a tighter binding of leukocytes to the vascular endothelium (Murphy et al., 
2007a). As a result of this enhanced adhesion, the rolling leukocytes arrest tightly to 
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the endothelium. Due to the adhesion immunglobulin-related molecules named 
PECAM (CD31), expressed on both the junction of the endothelial cells and 
leukocytes, enables leukocytes to squeeze between the endothelial cells 
(extravasation). With the help of enzymes that break down the basement membrane, 
the cells penetrate and migrate through the tissue under the influence of a 
concentration gradient of chemokines.  
 
 
I.3.2 CXCR4: Structure, Functions and Ligands 
CXCR4, a CXC chemokine receptor type 4 also named CD184 or fusin is a G-
protein-coupled receptor that was initially described as a leukocyte-derived seven-
transmembrane domain receptor (LESTR) (Herzog et al., 1993; Loetscher et al., 
1994). A few years later, after its isolation as a co-receptor for HIV-1 (Feng et al., 
1996) and the identifying of its ligand stromal-derived-factor-1 (SDF-1, also named 
CXCL12) (Bleul et al., 1996), an increasing interest to investigate the 
CXCL12/CXCR4 signalling pathway has developed.  
 
CXCR4 has 21 potential phosphorylation sites (Alkhatib, 2009). The chemokines 
SDF-1/CXCL12 and macrophage migration inhibitory factor (MIF) are ligands for 
CXCR4 that activate and signal through CXCR4, and mediate several cellular 
functions including immune responses, angiogenesis, and leukocyte trafficking (Viola 
and Luster, 2008). Binding of the ligand to CXCR4 induces a conformational change 
in the receptor, which allows the binding of the GTP-binding protein (G-protein) to the 
receptor (Wu et al., 2010). The intracellular G-protein functions as an intracellular 
signal by inhibiting or activating intracellular enzymes (Alkhatib, 2009). 
 
 
Stromal Cell-derived Factor-1, CXCL12 
Stromal cell-derived factor-1 (SDF-1) belongs to the CXC-chemokine subfamily (i.e. 
CXCL12) and is a highly effective lymphocyte chemoattractant (Bleul et al., 1996). 
Six isoforms have been identified so far; SDF-1 alpha, beta, gamma, delta, epsilon 
and phi (Yu et al., 2006). SDF-1 shows a 99% homology between human and 
mouse, allowing it to act across species. Unlike other chemokines, which are induced 
by inflammatory stimuli, SDF-1α is constitutively expressed in normal tissues like the 
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heart, spleen, and kidney (Takahashi, 2010). Besides its ability to induce chemotaxis, 
adhesion, and secretion of angiogenic factors and MMPs, SDF-1α regulates 
recruitment of bone marrow stem/progenitor cells, migration of endothelial cells and 
mobilization of EPCs and other progenitor cells from the bone marrow (Kucia et al., 
2004; Salcedo and Oppenheim, 2003; Schober et al., 2006). 
 
 
The CXCL12 / CXCR4 Axis in Myocardial Infarction 
The CXCL12 / CXCR4 system plays an important role in angiogenesis and 
myocardial infarction. Occlusion of a coronary artery results in myocardial ischemia, 
and hypoxia-related induction of HIF-1α. Secondary, HIF-1α increases the 
expression of CXCL12 and binding to and activation of its receptor CXCR4. 
 
Besides governing haematopoietic cell trafficking, CXCL12 has been shown to 
promote tissue regeneration by mediating the recruitment of progenitor cells into 
ischemic areas (Schober et al., 2006). Furthermore, CXCR4 signalling can stimulate 
proliferation and survival of different cell types, and angiogenesis (Kortesidis et al., 
2005; Vlahakis et al., 2002). After vascular injury, CXCL12 expression is up-regulated 
in response to apoptosis and is involved in CXCR4-dependent recruitment of smooth 
muscle progenitor cells to injured arteries (Schober et al., 2003; Zernecke et al., 
2005). Exogenous CXCL12 applied by myocardial injection, overexpressed in 
transplanted cardiomyocytes or nanofibre-delivered non-cleavable CXCL12, all 
induced therapeutic angiogenic/progenitor cell homing (Abbott et al., 2004; Askari et 
al., 2003), with increasing capillary density and improving cardiac function after 
myocardial infarction (Hu et al., 2007; Segers et al., 2007). Cardioprotective CXCL12 
activates the cell-survival factor protein kinase B (PKB/Akt) via CXCR4 and protects 
ischemic myocardium, decreasing scar size and mediating neovascularization in 
mice and rats (Saxena et al., 2008; Schuh et al., 2008). The interaction between 
CXCL12 and CXCR4 is increasingly exploited and was shown to enhance the 
efficacy of stem cell therapy after MI (Zhang et al., 2008; Zhang et al., 2007). In 
addition, over-expression of CXCR4 in mesenchymal stem cells enhanced 
mobilization and engraftment of mesenchymal stem cells (MSCs) into ischemic area 
in vivo improving cardiac function and left ventricular remodeling after myocardial 
infarction (Cheng et al., 2008; Zhang et al., 2008).  
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The intrinsic role of endogenous CXCL12/CXCR4 in MI, however, is far from being 
conclusively elucidated. For instance, administration of the selective CXCR4 
antagonist AMD3100 reduced scar formation and improved cardiac contractility after 
MI (Proulx et al., 2007). Moreover, CXCL12 can induce both survival and apoptotic 
signals via CXCR4, which may ultimately determine the fate of afflicted tissues 
(Vlahakis et al., 2002).  
 
 
 
 
Figure 8: The role of CXCL12/CXCR4 axis in myocardial infarction. After an occlusion of 
a coronary artery, low oxygen up-regulates the expression of HIF-1α that in turn induces the 
expression of CXCL12. Binding of CXCL12 to its receptor CXCR4 leads to cardioprotection 
and angiogenesis. Figure taken from: (Takahashi, 2010). 
 
 
Macrophage Migration Inhibitory Factor  
Macrophage migration inhibitory factor (MIF) is the first known member of the 
cytokine family and was originally described to be secreted by activated T-cells and 
to inhibit random movement and migration of macrophages (Bloom and Bennett, 
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1966; David, 1966). Despite its discovery many years ago, the human MIF was 
cloned first in 1989 and the molecular analysis of biochemical, biological, and 
biophysical properties have been elucidated in the past 20 years (Bernhagen et al., 
1993; Weiser et al., 1989). MIF is a unique protein lacking homology with any other 
pro-inflammatory cytokine (Donn and Ray, 2004). There is only one MIF gene 
present in humans and mice genome, located on chromosome 22 (22q11.2) in 
humans (Budarf et al., 1997) and on chromosome 10 in mice (Bozza et al., 1995), 
showing a similar gene structure (Bozza et al., 1995). In both species, MIF consists 
of 115 amino acids and has a molecular weight of 12.5 kDa (Bernhagen et al., 1994). 
Currently, a second MIF-like molecule, a protein encoded by the homolgous D- 
dopachrome tautomerase, D-DT gene was discovered (Merk et al., 2011). The genes 
for MIF and D-DT are located in close proximity to each and share 34% amino acid 
sequence identity confirming almost identical 3D structures. D-DT´s activation 
induced a MIF-like signaling cascade triggering the same immunologic pathways as 
MIF (Merk et al., 2011). 
 
Immune cells such as monocytes/macrophages, blood dendritic cells, T- and B-
lymphocytes, neutrophils, nature kill cells, basophils, mast cells and eosinophils 
express and secrete MIF (Apte et al., 1998; Bacher et al., 1996; Calandra et al., 
1994; Chen et al., 1998; Rossi et al., 1998; Takahashi et al., 1999). Different to most 
cytokines, MIF is quasi-constitutively expressed in mostly all tissues and stored in 
intracellular pools. Hence, a de novo protein synthesis is not needed for early MIF 
secretion (Calandra and Roger, 2003). Furthermore, several endocrine organs such 
as the anterior pituitary can produce and release MIF in high levels in response to 
LPS (lipopolysaccharides) stimulation. This points out that MIF plays a decisive role 
in the toxic response to endotoxemia and septic shock (Bernhagen et al., 1993; 
Bucala, 1996; Calandra et al., 2000).  
 
Currently, MIF is recognized to regulate innate and adaptive immunity, acting as a 
pro-inflammatory cytokine (Bernhagen et al., 1993) with “chemokine-like functions” 
(Degryse and de Virgilio, 2003). MIF has been linked to various acute and chronic 
inflammatory diseases such as septic shock (Bernhagen et al., 1993), 
glomerulonephritis, delayed hypersensitivity (Bernhagen et al., 1996), rheumatoid 
arthritis (Morand et al., 2006), and atherosclerosis (Zernecke et al., 2008a) by 
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regulating the recruitment of mononuclear cells to the site of inflammation (Calandra 
and Roger, 2003).  
 
 
 
 
 
 
 
 
 
Figure 9: The 3D cystal structure of mono-, di- and trimeric MIF. The images were 
created with PyMOL. Adapted to Sun et al., 1996.  
 
 
MIF has been described to bind with high affinity to the extracellular domain of CD74, 
a type II transmembrane protein. CD74 is also known as a MHC (major 
histocompatibility complex) class-II-associated invariant chain transporting MHC 
class II proteins. CD74 is required for MIF-induced activation of extracellular signal-
regulated kinase-1/2 (ERK1/2) MAP kinase cascade, cell proliferation and the 
production of prostaglandin E2 (PGE2) (Leng et al., 2003). CD74 functions in immune 
cell stimulation, in conjunction with CD44, a polymorphic transmembrane protein, 
which is widely expressed. The recruitment of CD44 into the MIF-CD74 complex 
might be essential for MIF signalling. Miller et al. demonstrated that MIF is secreted 
in the ischemic heart and enhances glucose uptake by stimulating the 
cardioprotective AMP-activated protein kinase (AMPK) pathway through CD74 (Miller 
et al., 2008).  
 
Bernhagen et al. identified the chemokine receptors CXCR2 and CXCR4 as 
functional non-cognate receptors for MIF in mediating monocyte/neutrophil and T cell 
recruitment into atherosclerotic lesions, and enhancing the formation and progression 
of atherosclerotic plaque (Bernhagen et al., 2007).  
 
CXCR2 is a proteotypic receptor for ELR-motif (ELR+) chemokines such as CXCL8 
(interleukin-8, IL-8) or CXCL1/GRO-α. The CXCL8/CXCR2 axis mediates 
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pathophysiological processes such as inflammatory leukocyte recruitment, cancer 
cell migration and angiogenesis (Addison et al., 2000; Charo and Ransohoff, 2006). 
Recently, flow cytometry, fluorescence microscopy, and pull-down analyses showed, 
that MIF function in atherogenesis is related to interaction of CXCR2 and CD74, 
which form a receptor complex regulating leukocyte recruitment and monocyte arrest 
to the endothelium. Treatment of Apoe-/- mice (apolipoprotein E–deficient mice) on a 
high fat diet with advanced atherosclerosis with anti-MIF antibodies led to plaque 
regression and decreased monocyte and T-cell content in the atherosclerotic plaque 
(Bernhagen et al., 2007; Schober, 2004). Besides CXCR2, MIF is also a functional 
ligand for CXCR4. Schwartz et al. demonstrated that CD74 is able to form a 
functional heteromeric complex with CXCR4 as well, and mediate MIF-specific 
signalling (Schwartz et al., 2009). 
 
Monocytes and macrophages have the ability to migrate within the tissue, to 
phagocytose and initiate immune responses. In addition, they are a major source of 
MIF, since they contain already pre-formed pools of MIF and MIF mRNA even in an 
unstimulated stage. The stimulation of macrophages by a variety of molecules, such 
as gram-negative bacteria endotoxin LPS, gram-positive bacterial exotoxin (toxic 
shock syndrome toxin1 TSST-1), and cytokines like TNF-α (tumor necrosis factor) 
and IFN-γ lead to an rapid secretion of MIF (Bernhagen et al., 1998; Calandra et al., 
1994; Calandra et al., 1998).  
 
MIF was identified to be the first protein secreted from monocytes/macrophages upon 
glucocorticoid stimulation (Bacher et al., 1996; Calandra et al., 1995). Glucocorticoid 
hormones modulate inflammatory and immune responses and are released within the 
systemic stress response by the pituitary gland. Low concentrations of 
glucocorticoids induce rather than inhibit MIF production from macrophages. Once 
released, MIF acts to override or counter-regulate the glucocorticoid-mediated 
inhibition of cytokine secretion (Calandra et al., 1995). T-cells also release MIF as an 
answer to glucocorticoid stimulation (Bacher et al., 1996). 
 
A number of recent studies imply that MIF is involved in processes regulating 
tumorigenesis, cell proliferation and angiogenesis. Takahashi et al. demonstrated the 
correlation between MIF expression and enhanced proliferation of murine carcinoma 
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cells (Takahashi et al., 1998). The administration of neutralizing anti-MIF antibodies 
to mice dramatically diminished the growth and the vascularization of 38C13 B 
lymphoma cells (Chesney et al., 1999). MIF stimulates in vivo the formation of new 
blood vessels (angiogenesis) in Matrigel plugs (Amin, 2003; Kanzler et al., 2012) 
whereas administration of the anti-MIF monoclonal antibody inhibits the 
neovascularization response (Chesney et al., 1999). Moreover, MIF induces the 
migration and tube formation of embryonic EPCs in Matrigel in vitro and was 
identified to be released by ecotropic human endometrial cells promoting endothelial 
cell growth (Yang et al., 2000).  
 
 
I.3.3 The Role of Chemokines and Cytokines in Myocardial Infarction and 
Peripheral Artery Disease 
Despite the fact that the role of chemokines in the pathogenesis of diseases such as 
atherosclerosis has been widely explored, the investigation regarding their role in 
myocardial infarction and PAD still remains incomplete.  
 
After an acute myocardial infarction, the plasma concentration of CC-chemokines 
such MCP-1/CCL2, macrophage inflammatory protein-1 alpha (MIP-1 alpha) and 
RANTES (Regulated on Activation Normally T-cell Expressed and Secreted) 
increases and is correlated with infarct complications including heart failure 
manifestations and severe left ventricular dysfunction (Parissis et al., 2002). In fact, 
the best-studied chemokine contributing to myocardial infarction is CCL2, an effective 
chemoattractant for monocytes, T cells and NK cells. 
 
In a myocardial reperfusion injury model in rats, the administration of an anti-CCL2 
antibody resulted in a reduction of the infarction size already 24 h after reperfusion 
and a decrease of infiltrated macrophages suggesting a pathophysiological function 
of CCL2 (Ono et al., 1999). Another study confirmed these findings, showing that an 
anti-CCL2 antibody treatment reduced macrophage recruitment and inflammatory 
cytokines such as tumor necrosis factor-α (TNF-α) and transforming growth factor-β 
(TGF-β) and furthermore improved contractility and dilation of the ventricle 
(Hayashidani, 2003). Surprisingly, a single intramyocardial injection of CCL2 into the 
infarct border zone did not change physiological parameters but induced neo-
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angiogenesis and monocyte infiltration (Schwarz et al., 2004). Finally, studies on 
CCR2- and CCL2-deficient mice revealed its involvement in myocardial remodeling, 
healing and inflammation after infarction (Dewald et al., 2005; Kaikita et al., 2004). 
Mice deficient in CCL2 demonstrated decreased and delayed macrophage 
recruitment in healing myocardial tissue after infarcts and delayed replacement of 
dead cardiomyocytes with granulation tissue leading to attenuated left ventricular 
function, whereas mice treated with neutralizing antibody against CCL2 showed no 
macrophage infiltration (Dewald et al., 2005). 
 
The chemokine ligand 5 (CCL5), also named RANTES has a role in neutrophil and 
macrophage activation. Treatment with a neutralizing monoclonal antibody (mAb) to 
mouse CCL5 resulted in a smaller infarct size and reduction of circulating levels of 
chemokines, associated with less macrophage and neutrophil infiltration within the 
infarcted heart. Furthermore, post-infarction heart failure was reduced, indicating for 
cardioprotective effects of blocking CCL5 (Montecucco et al., 2011). The expression 
of CCR5 binding chemokines macrophage inflammatory protein (MIP)-1α and MIP-1β 
were markedly induced after myocardial infarction, pointing out that CCR5 signaling 
prevents uncontrolled inflammation after infarction and protects from adverse 
remodeling by recruiting mononuclear cells (Dobaczewski et al., 2010).  
 
 
I.3.4 The Role of Chemokines and Cytokines in Endothelial Progenitor Cells 
Function 
As previously mentioned, the release of chemokines/cytokines in the proximity of 
angiogenic sites leads to the recruitment of monocytic EPCs, sustaining the process 
of new vessel formation by stimulation of EPC homing during vascular remodeling. 
Especially, the CC- and CXC- chemokines and their corresponding receptors play a 
pivotal role in this process. One example is CCL2-CCR2, which is not only involved in 
the processes of arteriogenesis and angiogenesis, but also in infiltration of circulating 
cells due to the receptor expression of CCR2 on endothelial and vascular smooth 
muscle cells (Buschmann et al., 2003; Goede et al., 1999; Weber et al., 1999). 
Furthermore, this receptor-ligand interaction also contributed to directing murine 
CCR2+ EPCs in tumor neovessels respectively to sites of arterial injury by a CCL2 
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dependent manner, leading to re-endotheliazation associated with the inhibition of 
neointimal hyperplasia (Fujiyama et al., 2003; Spring et al., 2005).  
 
Another CXC chemokine, namely CXCL12, mediates the adhesion, migration and 
homing of circulating progenitor cells, which are CXCR4-positive, to match the 
hypoxic gradients of the ischemic tissue (Ceradini et al., 2004). 
 
Another interaction between the CXC chemokine KC (keratinocyte-derived 
chemokine, CXCL1) and its corresponding receptor CXCR2 was described in 
leukocyte recruitment during inflammation (Smith et al., 2004). Moreover, in the case 
of endothelial dysfunction it sustains inflammatory and atherogenic monocyte 
recruitment, whereas the KC-CXCR2 axis was also suggested to be required for 
endothelial recovery after arterial injury (Liehn, 2004). KC is considered to have pro-
angiogenic effects on account of its role in promoting EPC arterial homing facilitating 
tumor growth (Haghnegahdar et al., 2000; Hristov et al., 2007a). A subpopulation of 
circulating EPCs (CD14+KDR+CXCR2+) was reported to be particularly efficient in 
facilitating endothelial recovery by incorporation at sites of denudation injury, and 
corresponding to cells with monocytic characteristics (Elsheikh et al., 2005; Hristov et 
al., 2007a). Thus, EPC homing to sites of denuded areas of arterial injury is 
dependent on CXCR2 and CXCR4 activation. Furthermore, the early EPC 
recruitment to the arterial injury site is mediated by CXCL12 and CXCL1 (Hristov et 
al., 2007b).  
 
Another instance where denudation occurs is after stent implantation. Here, a local 
administration of VEGF-A to the affected region leads to EPC attraction, achieving 
stent endothelialization and preventing restenosis (Walter et al., 2004). Homing of 
EPCs in case of an ischemic muscle, involves the adhesion of endothelial cells, 
incorporation to capillaries, transendothelial migration into extravascular space and in 
situ differentiation, is accelerated by VEGF leading to neovascularization (Hur et al., 
2007; Kawamoto et al., 2004).  
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II AIM OF THE STUDY 
 
The mechanisms of myocardial protection or regeneration conferred by the 
CXCL12/CXCR4 axis may involve both recruitment of circulating cells and effects on 
resident cardiomyocytes. I therefore wanted to study the function of CXCR4 in 
cardiac remodeling after MI in genetically modified mice to evaluate a potential 
relevance for unwanted effects of pharmacological compounds. 
 
Progenitor cell-based therapy including the use of EPCs, qualifies as a key to 
regenerate injured tissue and therefore is considered a great hope in treating 
ischemic diseases. Stem cell-induced angiogenesis, as a process of 
neovascularization depends on a cocktail of factors and involves multiple steps. MIF, 
VEGF, CXCL12 and CXCL1 are likely involved in this process. To better understand 
the behavior of EPCs in response to different growth factors, I wanted to evaluate the 
angiogenic potential of these different factors associated with the function of EPCs in 
angiogenesis.  
 
The pro-inflammatory cytokine MIF which also features chemokine-like functions 
plays a critical role in inflammatory diseases associated with attracting immune cells 
to sites of inflammation. MIF is known to promote angiogenesis and most growth 
factors that have been studied in detail have pleiotropic effects and induce both 
angiogenesis and arteriogenesis. The aim of this study was to analyze the role of MIF 
in arteriogenesis in a murine hind limb ischemia model. 
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III MATERIAL AND METHODS 
 
All solutions were prepared with double distilled water (Heraeus Destamat, Heraeus, 
Germany) or Millipore water (Milli-Q Plus ultrapure purification, Millipore, MA). 
Reagents were from Sigma-Aldrich (Deisenhofen, Germany), Roth (Karlsruhe, 
Germany), or Fluka (Buchs, Switzerland) if not stated otherwise. 
 
 
III.1 General Equipment 
Autoclave    Systec 2540EL (Systec, Wettenberg, Germany) 
Balance    Analytical Plus (Ohaus, Pine Brook, NJ, USA) 
Centrifuges Eppendorf 5424 (Eppendorf, Hamburg, Germany), 
Heraeus Labofuge 400, Heraeus Multifuge 3S-R 
(Heraeus, Osterode,Germany) 
Echocardiograph   Vevo 770 (Visual Sonics, Toronto Canada) 
Flow cytometers FACSCalibur, FACSAria (BD Biosciences, San 
Jose, CA, USA) 
Beckman Coulter FC500 cell sorter (Beckman 
Coulter, Inc., Fullerton, CA, USA) 
Fluorescence plate reader  SpectraFluor Plus (Tecan, Crailsheim, Germany) 
     Infinite M200 (Tecan, Gröding/Salzburg, Austria) 
Incubator    Hera Cell 240 (Thermoscientific, Bonn, Germany) 
Innova CO-48 (New Brunswick Scientific CO., 
Edison, NJ, USA) 
Laminar flow hood    Herasafe (Heraeus, Osterode, Germany) 
Langendorff apparatus UP-100 base (Hugo Sachs Elektronik-Harvard 
Apparatus, March-Hugstetten, Germany) 
Laser Doppler MoorLDI (Moor Instruments, Axminster, UK) 
Microscopes Olympus IX81, Olmypus SZX9 (Olympus Optical, 
Hamburg, Germany) 
Leica DM2500 (Leica, Wetzlar, Germany)  
Microtome    Leica RM 2135 (Leica, Wetzlar, Germany) 
PCR thermocyclers   MyCycler (Bio-Rad, Hercules, CA) 
pH-meter     InoLab level 1 (WTW, Weilheim, Germany) 
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RealTime PCR 7900HT Fast Real Time PCR System (Applied 
Biosystems, Darmstadt, Germany) 
Rodent respirator MiniVent TYPE 845 (Hugo Sachs Elektronik-Havard 
Apparatus, March-Hugstetten, Germany) 
Spectrometer    NanoDrop (Peqlab, Erlangen, Germany) 
 
 
III.2 General Solutions, Media and Buffers 
PBS  37 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM 
Na2HPO4, pH 7.4 (PAA laboratories) 
 
PFA  4% paraformaldehyde, 5% sucrose, 0.02 M EDTA, 
pH 7.4 
 
DMEM / Ham´s F-12  5% FBS, gentamycin (1:1000) 
 
Endothelial Cell  MV2 supplement mix, gentamycin (1:1000) 
Growth Medium M2  
 
RPMI 1640 medium with   10% FBS, 1% penicillin/streptomycin 
L-glutamine  
 
FACS staining buffer  PBS, 2% BSA, 2% mouse serum, 2% rabbit serum 
2% human serum 
 
Hanks´complete solution  1 x HBSS, 0.1% BSA, 5 mM EDTA 
 
HH-buffer Hank’s buffered salt solution (HBSS), 0.5% (w/v) 
BSA, 10 mM HEPES, pH 7.4 
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III.3 Chemokines/Cytokines and Recombinant Proteins 
The recombinant murine SDF-1α/CXCL12, KC/CXCL1 and VEGF165 were purchased 
from PeproTech. 
 
Biologically active recombinant mouse MIF and anti-MIF mAb (clone III D.9) was 
prepared and kindly provided by the Institute of Biochemistry and Molecular Cell 
Biology, University Hospital (UK) Aachen, Germany.  
 
In short summary: Overexpression of MIF was generated by using E.coli BL21, which 
was stored as cell pellet at -20°C and thawed on ice, homogenized and 
resuspended. All steps of cell lysis and protein purification were performed on ice. 
The lysis was implemented using an EmulsiFlex C-5 homogenizer. The cells were 
lysed in a single pass at a pressure of 15,000 psi and the cell debris were centrifuged 
for 30 min at 30,000 x g and 4°C. The supernatant containing the soluble proteins 
was collected and immediately used for purification. 
 
After protein determination, the first step of MIF purification was performed using an 
anion exchange chromatography in a FPLC (fast protein liquid chromatography) 
system with lowsalt-buffer. The column was pre-equilibrated and each run, 500 µl of 
the extract correlating with 1-5 mg total protein was applied. MIF is slightly basic and 
does not bind to the column. It was therefore eluted with the buffer and appeared in 
the first pass fraction. The MIF-containing fractions were pooled and the protein 
concentration was determined. The next purification step was performed by a 
hydrophobic chromatography using highsalt-buffers. The column was equilibrated 
with 10 ml methanol and 10 ml water before adding 2 mg protein to the column. 
Through subsequent washing steps low- and non-binding substances were removed. 
MIF was eluted with 60 % acetonitrile. After determining the protein concentration, 
the eluate was frozen at -80°C and then lyophilized. The lyophilisates were then 
stored at -20 ° C until further use. 
 
Lowsalt-buffer, pH 7,5    50 mM Tris-HCl + 150 mM NaCl 
Highsalt-buffer, pH 7,5    50 mM Tris-HCl + 2 M NaCl 
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III.4 Antibodies 
 
III.4.1 Primary Antibodies 
CXCR2  Rabbit anti-mouse pAb (GeneTax) 
CXCR4  Goat anti-mouse pAb (Lifespan Biosciences) 
CD74   Goat anti-mouse pAb (Santa Cruz Biotechnology) 
MIF   Rabbit anti-mouse pAb (Invitrogen) 
Mac2 Rat anti-mouse mAb (clone M3/38, Cedarlane Laboratories) 
α-SMA  Mouse anti-human mAb (clone 1A4, Dako) 
CD3    Rat anti-mouse mAb (clone KT3, Serotec) 
CD31   Goat anti-mouse mAb (clone M-20, Santa Cruz Biotechnology) 
F4/80   Rat anti-mouse mAb (clone CI:A3-1, Serotec) 
 
 
III.4.2 Isotype Controls 
Normal goat IgG  Santa Cruz Biotechnology 
Normal rat IgG  Santa Cruz Biotechnology 
Normal rabbit IgG  Santa Cruz Biotechnology 
 
 
III.4.3 Secondary Antibodies 
Donkey anti-rat IgG  Cy3-conjugated (Jackson ImmunoResearch) 
Donkey anti-mouse IgG  FITC-conjugated (Jackson ImmunoResearch) 
Donkey anti-rat IgG  FITC-conjugated (Jackson ImmunoResearch) 
Donkey anti-goat IgG FITC-conjugated (Jackson ImmunoResearch) 
 
 
III.4.4 Directly Conjugated Antibodies 
CD31-PE-Cy7  Rat anti-mouse mAb (clone 390, Abcam) 
VEGF2R-PE   Rat anti-mouse mAb (clone AVAS 12α1, BD Biosciences) 
CXCR4-PE Rat anti-mouse mAb (clone 2B11/CXCR4, BD 
Biosciences) 
CXCR4-FITC Rat anti-mouse mAb (clone 2B11/CXCR4, BD 
Biosciences) 
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CXCR2-PE   Rat anti-mouse mAb (clone 242216, R&D Systems) 
CD74-FITC   Rat anti-mouse mAb (clone In-1, BD Biosciences) 
CD11b-FITC Rat anti-mouse mAb (clone M1/70, eBioscience) 
CD11b-PE-Cy7  Rat anti-mouse mAb (clone M1/70, BD Bioscience) 
CD45-APC-Cy7 Rat anti-mouse mAb, leukocyte marker (clone 30-F11, BD 
Biosciences) 
CD115-PE Rat anti-mouse mAb, monocyte marker (clone AFS98, 
eBiosciences) 
Gr-1-PerCP Rat anti-mouse mAb, mature granulocyte marker (clone 
RB6-8C5, BD Biosciences) 
Ly6C-PE   Rat anti-mouse mAb (clone 1G7.G10, Miltenyi Biotec) 
Ly6C-FITC   Rat anti-mouse mAb (clone 1G7.G10, Miltenyi Biotec) 
 
 
III.4.5 Blocking Antibodies 
Anti-VEGF164  Goat anti-mouse mAb (R&D Systems) 
Anti-CXCL12/SDF-1α  Mouse anti-human/mouse mAb (clone 79014, R&D 
Systems)  
Anti-CXCL1/KC  Rat anti-mouse mAb (clone 124014, R&D Systems)  
 
 
III.5 Mice 
Wildtype C57BL/6J and CXCR4+/- mice were obtained from P. Gierschik, University 
of Ulm and C57BL/6J (Charles River, Chatillon-sur-Chalaronne, France) CXCR4+/+ 
littermates served as controls. 
 
Mice lacking CXCR4 die perinatally and display profound defects in vascular 
development, hematopoiesis, and cardiogenesis including severely deficient B-
lymphopoiesis, reduced myelopoiesis in fetal liver, and virtual lack of myelopoiesis in 
the bone marrow (Ma et al., 1998; Tachibana et al., 1998). Therefore, we chose to 
assess the effects of reduced CXCR4 expression after MI in mice heterozygous for 
CXCR4, which appear normal, are viable and fertile (Ma et al., 1998) although 
CXCR4 surface expression on bone-marrow derived mononuclear cells from 
CXCR4+/- mice is significantly lower compared to wild-type mice (Walter et al., 2005). 
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All animal experiments were approved either by local authorities and complied with 
German animal protection law (50.203.2-AC 37, 26/05; -AC 36, 19/05) or by Animal 
Care and Use committee of the University of Maastricht (2009-077) and were 
performed according to official rules formulated in the Dutch law on care and use of 
experimental animals. 
 
 
III.6 Cell culture and Cell Isolation 
Cell culturing was performed under sterile conditions in a laminar flow hood. All cells 
were cultured at 37°C in a humidified 5% CO2 incubator. The medium was changed 
every 2 days. Fetal bovine serum (FBS), a supplement added to culture medium was 
incubated at 56°C for 30 min to inactivate complement proteins and stored as 
aliquots at -20°C until use. 
 
 
III.6.1 Cell Culturing of WEHIs and SVECs 
Simian virus 40-immortalized murine endothelial cells (SVECs) were cultured in 
Dulbecco's modified eagle's medium/Ham´s F-12 supplemented with 5% FBS and 
gentamycin (1:1000).  
 
The mouse monocytic cell lines, WEHI 274.1 was obtained from the American Type 
Culture Collection (Rockville, MD, USA) and grown in RPMI 1640 medium with L-
glutamine (PAA, E15-840) supplemented with 10% FBS and 1% penicillin/ 
streptomycin. 
 
 
III.6.2 Isolation of Angiogenic Early Outgrowth EPCs  
Early outgrowth endothelial progenitor cells (EPCs) were derived from spleens of 
male C57BL/6J wild-type and CXCR4+/- mice. Spleen tissue was minced using a 
syringe plunger and filtered through a mesh with 40 µm pore size. Mononuclear cells 
were separated from erythrocytes, dead cells, and tissue debris by density gradient 
centrifugation (Lympholyte®-Mammal, Cedarlane Lab) at 800 x g for 20 min without 
brake. After washing the mononuclear cells with PBS, cells were resuspended in 
microvascular endothelial growth medium MV2 (PromoCell), containing a supplement 
MATERIAL AND METHODS 
37 
mix (C-39226) and gentamycin (1:1000) to avoid contamination with bacteria, and 
plated in a 6-well plate coated with bovine fibronectin. After four days of culturing, 
medium was changed and non-adherent cells were removed. At day ten, adherent 
cells were harvested using accutase, counted and used for further experiments.  
 
 
III.6.3 Cardiomyocyte Isolation and Hypoxia Experiments 
Cardiomyocytes were isolated from wildtype or CXCR4+/- hearts using the Adult M/R 
Cardiomyocyte Isolation System (Cellutron). After isolation and seeding, cells were 
cultured in AW medium (without serum, Cellutron). Hypoxia experiments were 
performed using an Innova CO-48 incubator with O2 control (1% O2, 5% CO2) (New 
Brunswick Scientific) and hypoxic buffer (HB, 137 mM NaCl; 3.8 mM KCl; 0.49 mM 
MgCl2; 0.9 mM CaCl2; 4 mM Hepes; supplemented with 10 mM 2-deoxi-glucose; 20 
mM sodium lactat; 10 mM sodium ditionit; 12 mM KCl; pH6,2). Cardiomyocytes were 
incubated with phosphatidylserine (PS) from bovine brain (Sigma) for 3 h before 
hypoxia. After 1 h of hypoxia, the stress rate was determined by adding 
dihydroethidium (DHE, Sigma). Stained cells were counted using a fluorescence 
microscope in five high-power fields and expressed as percentage of total cells. 
 
 
III.6.4 Isolation of Blood Monocytes 
Murine blood was collected from C57BL/6J mice by cardiac puncture using a syringe 
containing 0.2 ml citrate. Between 1000 and 1500 µl of blood was collected per 
mouse and diluted with an equal volume of PBS. Cell suspension was loaded on top 
of Lympholyte®-Mammal and centrifuged at 800 × g for 20 min without the brake. 
PBMCs were collected from the interface and centrifugated at 800 × g for 10 min. 
Cells were then resuspended in RPMI 1640 medium with L-glutamine (PAA, E15-
840) supplemented with 10% FBS and 1% penicillin/ streptomycin and cultured in 6-
well plates. 
 
 
III.6.5 Isolation of Bone Marrow-Derived Monocytes  
In the presence of M-CSF, mononuclear phagocyte progenitor cells derived from 
femoral and tibia bone marrow. This macrophage growth factor is secreted by L929 
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cells and is used in the form of L929 cell-conditioned medium (LCM) (Stanley and 
Heard, 1977). Progenitor cells proliferate and differentiate through monoblast, 
promonocyte and monocyte stages before maturing into macrophages. At this time 
point, these cells firmly adhere to the bottom of the culture flask. 
 
For cell isolation, mice were killed by isoflurane and femur and tibia were removed 
and dissected free from the adherent tissue. Both ends of femur and tibia were cut off 
and PBS was injected into the bone to flush out the bone marrow tissue in a sterile 
falcon tube. Cells were dispersed by pipetting and centrifuged at 1200 rpm for 5 min 
at 4°C. After resuspending in culture medium, the monocytes were plated in 15 cm 
bacterial plastic plate containing 20 ml culture medium + 15% LCM. After 3 days, 10 
ml medium was added and after 6 days, replaced by new medium with 15% LCM. 
After 8 days, medium was discarded and macrophages were lifted with pre-warmed, 
filtered 4 mg/ml Lidocaine/10 mM EDTA/PBS solution. After centrifugation, cells were 
counted and plated in 6-well plates as required.  
 
Macrophages were incubated with rmMIF (5 ng/ml, 10 ng/ml, 50 ng/ml, 100 ng/ml, 
200 ng/ml, 400 ng/ml, 500 ng/ml) at 37°C, for 24 h. Macrophages were lysed for 
mRNA isolation. 
 
 
III.7 Biomolecular Methods 
 
III.7.1 mRNA Isolation and Reverse Transcription - Polymerase Chain Reaction 
mRNA from hearts was isolated with TRIzol Reagent (Gibco) and after reverse 
transcription (Omniscript Kit, Qiagen), PCR was performed using specific 
oligonucleotide primers (Table 1). 
 
 
Table 1: Specific oligonucleotide primers used in this study 
Mouse CXCL12  forward primer: 5’-GTCAGCCTGAGCTACCGATG-3’ 
reverse primer: 5’-GGGTCAATGCACACTTGTCTGT-3’  
Mouse VEGFA forward primer: 5’-CCTGGCTTTACTGCTGTACCTC-3’ 
reverse primer: 5’-GTGCTGTAGGAAGCTCATCTCTC-3’ 
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Mouse  
VE-cadherin 
forward primer:5’-ACTGTGATGATCAGACTGGAGGAC-3’ 
reverse primer: 5’-GTCTGTCTCAATGGTGAAGGTGTC-3’ 
Mouse vWF forward primer: 5’-ACTTCTGCAGACCTGCGTAGAC-3’ 
reverse primer: 5’-CCTCAACATATGGGGTGGTAGA-3’ 
Mouse Bax forward primer: 5’-TGCAGAGGATGATTGCTGAC-3’ 
reverse primer: 5’-GATCAGCTCGGGCACTTTAG-3’ 
Mouse Bcl2 forward primer: 5’-AGGAGCAGGTGCCTACAAGA-3’ 
reverse primer: 5’-GCATTTTCCCACCACTGTCT-3’ 
Mouse ß-actin forward primer: 5’-AGCCATGTACGTAGCCATCC-3’ 
reverse primer: 5’-CTCT CAGCTGTGGTGGTGAA-3’ 
 
 
III.7.2 Quantification of RNA and Quantitative Real-Time Polymerase Chain 
Reaction 
To determine gene expression of different M1 (IL12, TNF-α, iNOS) and M2 (IL10, 
YM1, FIZZ-1) macrophage markers, as well as the expression of MIF and its 
receptors CXCR2, CXCR4, and CD74 after stimulation with different rmMIF 
concentrations for 24 h, a real time PCR was performed using the MaximaTM SYBR 
Green qPCR Master Mix and specific primer pairs (Table 2). The SYBR Green dye 
binds to double-stranded DNA, and after excitation emits light, providing a fluorescent 
signal, which reflects the amount of double-stranded DNA product generated during 
the PCR. Thus, as a PCR product accumulates, the fluorescence signal increases 
and can be directly detected. The advantage of SYBR Green is that it is easy in 
using, sensitive and not expensive. On the other hand, it binds to any double-
stranded DNA in the reaction, which includes non-specific binding and primer-dimers, 
potentially resulting in an overestimation of the target concentration. 
 
mRNA from macrophages was isolated using ZR RNA MicroPrep™. After measuring 
the amount of RNA, 1µg total RNA was reverse-transcribed into cDNA and 20 ng 
cDNA was used per real-time PCR reaction. The housekeeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as a reference gene. 
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Reverse transcription: 2 µl hexamer primer 
    4 µl reaction buffer 
    2 µl 5mM dNTPs 
    1 µl reverse transcriptase 
    2 µg template RNA 
    H2O to a final volume of 20 µl 
 
Real time-PCR:  2 µl cDNA 
    12.5 µl MaximaTM SYBR Green qPCR Master Mix 
    2.5 µl forward primer (2 µm) 
    2.5 µl reverse primer (2 µm) 
    5.5 µl RNase free water 
 
Real time-PCR program: Initial activation 95°C, 15 min 
    Denaturation of cDNA 95°C, 30 sec 
    Annealing of primers 58°C, 30 sec          x 40 
    Elongation of primers 72°C, 30 sec 
    95°C, 2 min 
    60°C, 2 min 
 
The relative mRNA expression is calculated as follows: 
∆Ct = Ct (target gene) – Ct (reference gene) 
∆∆Ct = ∆Ct (sample) – ∆Ct (control sample) 
Relative mRNA expression: 2-( ∆∆Ct) 
Ct: Cycle number at which the fluorescence intensity exceeds a determined threshold 
 
 
Table 2: Primers for real-time PCR used in this study (Sigma) 
Mouse CXCR2  forward primer: 5’-GCCTTGAGTCACAGAGAGTTG-3’ 
reverse primer: 5’-CAAGGCTCAGCAGAGTCAC-3’  
Mouse CXCR4 forward primer: 5’-GGCTGTAGAGCGAGTGTTG-3’ 
reverse primer: 5’-CAGAAGGGGAGTGTGATGAC-3’ 
Mouse CD74 forward primer: 5’-CCCATTTCTGACCCATTAGT-3’ 
reverse primer: 5’-TGTCCAGCCTAGGTTAAGGGT-3’ 
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Mouse MIF forward primer: 5’-TTTAGCGGCACGAACGATCC-3’ 
reverse primer: 5’-CGTTGGCAGCGTTCATGTC-3’ 
Mouse YM1 forward primer: 5’-TGGCCCACCAGGAAAGTACA-3’ 
reverse primer: 5’-CAGTGGCTCCTTCATTCAGAAA-3’ 
Mouse IL10 forward primer: 5’-TTTGAATTCCCTGGGTGAGAA-3’ 
reverse primer: 5’-CTCCACTGCCTTGCTCTTATTTTC-3’ 
Mouse TNF-α  forward primer: 5’-CATCTTCTCAAAATTCGAGTGACAA -3’ 
reverse primer: 5’-TGGGAGTAGACAAGGTACAACCC-3’  
Mouse IL12 forward primer: 5’-GGTGCAAAGAAACATGGACTTG-3’ 
reverse primer: 5’-CACATGTCACTGCCCGAGAGT-3’ 
Mouse FIZZ-1 
 
forward primer:5’-GGAACTTCTTGCCAATCCAG-3’ 
reverse primer: 5’-ACACCCAGTAGCAGTCATCCC-3’ 
Mouse iNOS forward primer: 5’-TTGCAAGCTGATGGTCAAGATC-3’ 
reverse primer: 5’-CAACCCGAGCTCCTGGAA-3’  
Mouse GAPDH forward primer: 5’-ATTGTCAGCAATGCATCCTG-3’ 
reverse primer: 5’-ATGGACTGTGGTCATGAGCC-3’ 
 
 
III.8 Protein Assays 
 
III.8.1 Flow Cytometry Analysis 
Flow cytometry is the measurement of cells in a flow system, which can be used to 
analyze cells according to their size, granularity and protein expression or sorting cell 
populations (FACS = fluorescent activated cell sorting). One cell at a time, 
suspended in a stream of fluid buffer, passes through a light beam that excites 
fluorescently labeled cells. Measurements of size (forward scatter) and granularity 
(sideward scatter) are independent from the fluorescence signal. 
 
Flow cytometry measurements were performed by using the corresponding, 
fluorescence labelled antibodies in Hank´s balanced salt solution containing 0.1 % 
bovine serum albumin (BSA) and 0.3 mmol/l ethylenediaminetraacetic acid (EDTA). 
 
Blood and digested hearts were resuspended in FACS staining buffer with specific 
fluorescence-conjugated antibodies, anti-CD45-APC-Cy7, anti-CD115-PE and anti-
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Gr-1-PerCP to determine monocyte subpopulations (Nahrendorf et al., 2007). To 
analyze endothelial cells and apoptosis, anti-CD31-PE-Cy7, anti-VEGF2R-PE, 
Annexin-V-FITC (BD Bioscience) staining was performed. Annexin V is a 
phospholipid-binding protein that has a high affinity for phosphatidylserine, which 
translocates from the inner to the outer leaflet of the plasma membrane in the early 
stages of apoptosis. The staining is therefore an important tool to identify apoptosis. 
To determine CXCR4 expression on blood cells an anti-CXCR4-PE was used.  
 
Isolated EPCs were characterized by, anti-CD31-PE-Cy7, anti-VEGF-R2-PE, and 
anti-CD11b-FITC staining. To examine the expression of the MIF receptors on the 
cell surface, the cells were stained with anti-CXCR2-PE, anti-CXCR4-PE and anti-
CD74-FITC.  
 
In vivo shifts in monocyte populations, as a result of administration of rmMIF or anti-
MIF mAb during arteriogenesis, were analyzed after whole blood was drawn from the 
heart of the animals. After erythrocyte lysis, cells were stained with anti-CD11b-PE-
Cy7, anti-Ly6C-PE, anti-Ly6C-FITC, and anti-CXCR2-PE in three different antibody 
mixes per animal. All samples were incubated with antibodies on ice and in the dark 
for 20-30 min, washed with Hanks´ complete and analyzed immediately by flow 
cytometry using a FACS Canto II flow cytometer and FLOW JO Software. Non-
stained cells served as controls. Cell sorting was performed with the Beckman 
Coulter FC500 cell sorter (Beckman Coulter, Inc., Fullerton, CA, USA) and analyzed 
with Kaluza® Analysis Software.  
 
 
III.8.2 Histochemistry and Immunohistochemistry 
 
Histomorphometry and Determination of Myocardial Infarction Size 
Serial sections of the hearts (10-12 per mouse, 400 µm apart, up to the mitral valve) 
were stained with Gomori’s 1-step trichrome stain. The infarcted area was 
determined in all sections using Diskus software (Hilgers) and expressed as 
percentage of total left ventricular volume.  
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To measure the area at risk one day after MI, a staining with tetrazolium (Sigma) was 
performed. Briefly, hearts were cut into 2 mm thick slices, which were incubated with 
TTC (2,3,5-triphenyltetrazolium chloride). TCC is a redox indicator, which is used to 
distinguish between metabolically active and inactive tissue due to the activity of 
dehydrogenases in living tissues. This enzyme reduces the white compound to red 
colour compound. After the TTC staining, the hearts were fixed with formalin, and 
pressed between glass blades to achieve uniform thickness. The pale infarcted area 
was determined in all sections using Diskus software (Hilgers) and expressed as 
percentage of total left ventricular area. 
 
 
Cellular Stainings of Inflammatory Cells in the Heart 
Serial sections of the hearts (3 per mouse, 400 µm apart) were stained to analyze the 
infarcted areas for the content of neutrophils (specific esterase, Sigma), 
macrophages (F4/80), lymphocytes (CD3), vessels (CD31/PECAM), and 
myofibroblasts (α-smooth muscle actin). Cells or vessels were counted in 6 different 
fields per section and expressed as cells or vessels/mm².  
 
To determine apoptosis in the hearts, serial sections (3 per mouse, 400 µm apart) 
were stained with In Situ Cell Death Detection Kit (Roche), and counter-stained with 
DAPI. Apoptotic cell indexes were expressed as percentage of positive from total 
cells.  
 
 
Cellular Stainings of Receptors and MIF in Hindlimb Tissue 
Serial sections of the hindlimbs (5 per mouse, 5 µm thick) were stained to analyze 
the content of macrophages (Mac2), as well as the chemokine MIF and its 3 
receptors CXCR2, CXCR4, and CD74. Cells were numbered in 6 different fields per 
section and absolute number of cells expressing Mac2 and CXCR2 were counted. 
For CD74 expression, percentage of total cell surface per field, for CXCR4 
expression, pixel per field and for MIF expression, percentage of positive tissue per 
field was analyzed. 
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III.8.3 AcLDL and Lectin Uptake 
EPCs were incubated at 37°C with 10 µg/ml DiI-labelled acLDL (Cell Systems). After 
two hours, the cells were fixed with paraformaldehyde (1%) for 10 min and 
subsequently incubated with biotinylated Griffonia Simplicifolia lectin I (100 µg/ml) for 
1 hour followed by streptavidin-FITC. Finally, cells were mounted (Vectashield with 
DAPI, Vector Lab) and analyzed by fluorescence microscopy. 
 
 
III.9 Functional Assays 
 
III.9.1 Chemotaxis Assay 
Chemotaxis assay was performed using a 24-well transwell cell culture chamber with 
BD Falcon® HTS FluoroBlokTM 3.0 µm colored PET membrane inserts. Serum-
starved wild-type and CXCR4+/- EPCs were resuspended in assay medium MV2 
containing 0.5% BSA. 20,000 cells in 100 µl medium were applied on top of 
membrane insert filters. Test factors (rmVEGF (50 ng/ml, 100 ng/ml)), rmSDF-1α (50 
ng/ml, 100 ng/ml), rmKC (50 ng/ml), rmMIF (50 ng/ml)) or buffer control were added 
in 600 µl assay medium and placed in the lower chamber. After incubation at 37°C 
for 2 h, migrated cells were quantified on the bottom side of the filter after DAPI 
staining and were counted manually using a fluorescence microscope. 
 
 
III.9.2 Transmigration Assay 
To compare the migratory effect of chemokines and growth factors, a transmigration 
assay was performed using a 24-well transwell cell culture chamber with Falcon® 
HTS FluoroBlokTM 3.0 µm colored PET membrane inserts. Brd-U marked SVECs 
were placed on top of fibronectin-coated filters with 100 µl DMEM/Ham´s F-12 
medium. After incubation at 37°C for 24 h, SVECs form an endothelial monolayer on 
the membrane surface. Inserts were subsequently placed in a new 24-well plate 
whereby the lower chamber was containing 600 µl assay medium plus the test 
factors (rmVEGF (50 ng/ml), rmSDF-1α (50 ng/ml), rmKC (50 ng/ml), rmMIF (50 
ng/ml), anti-MIF mAb (10 µg/ml). Serum-starved EPCs and WEHIs were 
resuspended in assay medium MV2 and RPMI containing 0.5% BSA, respectively. 
20,000 cells in 100 µl were applied on top of each insert filter. After incubation at 
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37°C for 2 h, transmigrated cells on the bottom side of the filter were stained with 
DAPI and were counted using a fluorescence microscope.  
 
 
III.9.3 Static Cell Adhesion Assay 
Static adhesion assay was performed using a 96-well plate. For an endothelial 
monolayer, 10,000 SVECs were placed in each well at 37°C for 24 h. WEHIs (20,000 
or 50,000 cells per well) or isolated blood monocytes (20,000 cells per well) were 
labelled with calcein-AM (1 µg/ml). Calcein-AM is a cell permeable compound, which 
can be transported through the cellular membrane into living cells. There it is 
converted to the strong green fluorescent calcein after hydrolyzing (removing of the 
acetomethoxy group) by intracellular esterases. Test factors, rmMIF (10 ng/ml, 50 
ng/ml, 100 ng/ml) and anti-MIF mAb (10 µg/ml, 20 µg/ml) were added to the assay 
medium containing calcein-labelled WEHIs or blood monocytes After incubation for 
16 h at 37°C, non-adherent cells were removed by washing the cells with PBS. 
Adherent monocytes were analyzed by multiple fluorescence top reading (excitation 
480 nm, emission 520 nm) using TECAN® i-control reader and i-control software. 
 
 
III.9.4  Flow Cell Adhesion Assay 
Chemoattractants recruit monocytes to sites of inflammation, where they adhere to 
the endothelium and transmigrate through the vessel wall. To study the arrest of 
monocytes under shear stress, adhesion of WEHIs to an endothelial SVEC 
monolayer was analyzed under laminar flow conditions. SVEC cells were grown to 
confluence in 35 mm dishes coated with collagen and stimulated with TNF-α (10 
ng/ml, for 2 h at 37°C) to induce adhesion molecule expression. Calcein-labelled 
WEHIs (1x106 cells/ml) were then directly incubated with 100 ng/ml rmMIF, 10 µg/ml 
anti-MIF mAb or PBS for 30 min at 37°C and perfused at 1.5 dyn/cm2 in HH buffer. 
After 5 min, the number of adherent cells was quantified in multiple fields by analysis 
of images recorded with a long integration 3CCD video camera (JVC, Japan).  
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III.9.5 Matrigel Assay in vitro 
BD Matrigel™ Basement Membrane Matrix was thawed overnight at 4°C. 300 µl 
matrigel was placed in each well of a 24-well plate and allowed to polymerize at 37°C 
for 30 min. EPCs (1x105 cells/ml/well) were labelled with calcein-AM for 30 min at 
37°C and seeded together with murine endothelial cells (SVECs, 3x104 cells/ml/well) 
in a cell suspension in assay medium on top of the matrigel. The cells were 
stimulated either with rmVEGF (50 ng/ml), rmSDF-1α (50 ng/ml), rmKC (50 ng/ml), or 
rmMIF (50 ng/ml). After incubation at 37°C for 24 h, tube formation ability was 
quantified by counting the total number of tube-like structures in 5 random 
microscopic fields. 
 
 
III.9.6 Electron Microscopy 
Samples were fixed in 3% glutaraldehyde for 14 h, washed with 0.1 M B2 buffer 
(pH7.4; 13 mM NaH2PO4; 87 mM Na2HPO4) overnight, followed by 1 hour in 1% 
OsO4 (in 17% sucrose buffer - pH7.4; 88 ml 0.1 M B2 buffer; 12 ml H2O, 17 g 
sucrose), rinsed with water and dehydrated with ethanol (30% - 100%) and 
propylenoxide (100%). Finally, tissues were processed for embedding in Epon, 
polymerized for 48 h at 60°C, cut into 80-100 nm thick slices and contrasted with 
uranyl acetate and lead citrate. The samples were analyzed with a PHILIPS EM 400 
T at 60 kV and micrographs were taken by an OLYMPUS CCD-Camera MORADA. 
 
 
III.9.7 Lipid Extraction and HPLC  
For lipid extraction, hearts were shock-frozen in liquid nitrogen. After mincing the 
tissue, chloroform and methanol were added (1:2, 0.5 ml per 150 mg tissue) for 15 
min under shaking conditions. Finally, chloroform and water (1:1, 0.2 ml per 150 
initial tissue) were added and the samples were centrifuged at 3,000 rpm for 7 min. 
The lower phase was separated and lyophilized under nitrogen atmosphere. 
Phospholipid extracts from mouse hearts were separated by HPLC. Briefly, dried lipid 
films were dissolved in solvent A (hexane–2 isopropanol, 6:8 v/v) and injected in a 
Spectrasystem 2000 HPLC device with a Betasil Silica-100 column (250×4 mm) from 
ThermoFischer Scientific (Dreieich, Germany). A linear gradient was applied from 0-
100% solvent B (hexane–2 isopropanol–water, 6:8:1.4 v/v/v) over 45 min at 1 ml/min 
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and lipids were detected at 206 nm. Mobile phases were from Carl Roth GmbH 
(Karlsruhe, Germany). Peaks were identified using standards for triglyceride, 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and 
phosphatidylinositol (Sigma).  
 
 
III.9.8 Gas-Chromatography of Fatty Acids 
HPLC-isolated lipid fractions were solubilized in hexane and transesterification was 
done using 2 M potassium hydroxide in methanol. After adding anhydrous sodium 
sulfate for drying, the solution was vigorous mixed. Next, the filtered solution was 
neutralized with sodium phosphate monobasic and concentrated in a rotary 
evaporator. The methylester solution was injected in a Thermo Fischer TR-FAME 
capillary column (120m x 0.25mm I.D. x 0.25 µm) of a CP-3800 VARIAN gas 
chromatographer system, equipped with a flame-ionization detector. Peaks were 
identified according to fatty acid standards (FAME MIX 37, Sigma-Aldrich) and 
analyzed using automated integration. 
 
 
III.10 Animal Experiments 
 
III.10.1 Murine Model of Myocardial Infarction 
The myocardial infarction surgical procedure in mice imitates the pathobiological and 
pathophysiological aspects which occur in infarction-related myocardial ischemia 
(Kolk et al., 2009). CXCR4+/- mice (C57BL/6J) were obtained from P. Gierschik, 
University of Ulm. CXCR4+/+ littermates served as controls. After intubation under 
general anaesthesia (100 mg/kg ketamine, 10 mg/kg xylazine, i.p.) mice were 
positive pressure ventilated with oxygen and 0.2% isofluran using a rodent respirator 
(Liehn et al., 2008). Hearts were exposed by left thoracotomy and MI was produced 
by permanent ligation of the left anterior descending artery (LAD) with suture ligation. 
This procedure forms ischemia that can be seen almost immediately after ligation. By 
closing the LAD, no further blood flow is allowed in that area, whereas the 
surrounding myocardial tissue is almost not affected. Muscle layer and skin incision 
were closed with a silk suture.  
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Figure 10: Ligation of the LAD. The heart of the mouse with the pattern of left coronary 
arteries and the position of the permanent ligation of the left anterior descending artery as 
performed in the MI procedure (adapted from (Wang et al., 2006)). 
 
 
III.10.2 Bone Marrow Reconstitution 
Bone marrow chimeras were established as described (Lutgens et al., 2010). Wild-
type or CXCR4+/- mice received 12 Gray split into two doses. Recipient mice were 
reconstituted with 2×106 CXCR4+/- or wild-type bone-marrow cell injection i.v., 
respectively. After six weeks, mice were subjected to MI. At the indicated time points, 
blood samples were taken for leukocyte analysis. Four weeks after the infarction, the 
hearts were taken for further analysis. 
 
 
III.10.3 Ultrasound Analysis  
Two-dimensional and M-mode (Time-motion mode) echocardiographic 
measurements (Vevo 770, Visual Sonics, Toronto, Canada) were performed before 
and after induction of MI. Mice were anesthetized with 1.5% isofluran via a mask and 
placed in the supine position on a warming pad. The chest hair was removed and the 
limb leads were attached to the pad. Ejection fraction, fractional shortening, cardiac 
output, stroke volume, left ventricular end-diastolic and end-systolic dimensions was 
quantified according to standard protocols (Liehn et al., 2008; Liehn et al., 2010).  
 
 
III.10.4 Langendorff Perfusion 
Langendorff perfusion is an in vitro technique to study the cardiac contractile 
strength, the heart rate, and coronary resistance under known physiological 
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conditions without the hormonal and neural complications of an in vivo animal 
experiment. After the heart is removed from the animal, the ascending aorta is 
cannulated and the heart is then perfused in a reverse fashion via the aorta with a 
nutrient rich oxygenated solution. The backwards pressure causes the aortic valve to 
close, forcing the solution into the coronary circulation, which usually provides the 
heart tissue with blood. This feeding solution allows the heart to continue contractions 
for several hours and heart parameters can be analyzed.  
 
At indicated time points, mice were anesthetized with Ketamin (100 mg/kg) and 
Xylazin (10 mg/kg) and heart function was analyzed using a Langendorff apparatus 
and Isoheart software under constant perfusion pressure (100 mmHg) and electrical 
stimulation to assure constant heart rates (600 bpm). Coronary flow and developed 
pressure were measured. Finally, hearts were fixed with 10% formalin, paraffin 
embedded and cut into 5 µm serial slices and used for further analysis.  
 
 
III.10.5 Vessel Density (High-Resolution Computer Tomography) 
For coronary visualization, six mice (three knock-out mice, three wild-type mice) were 
studied using high-resolution computer tomography. After anesthesia and midline 
laparotomy, mice were bled to death; the hearts were exposed, retrogradely perfused 
and fixed with 4% paraformaldehyde. Subsequently, hearts were perfused with 
Microfil®, a lead-containing contrast agent, which polymerises intraluminally, 
extracted and scanned in a SkyScan1172 micro-CT (SkyScan, Belgium) by acquiring 
681 projections with 1048x2000 pixels at an increment of 0.3°. Reconstruction voxel 
size was 5.36 µm. All direct branches of the left and right coronary arteries were 
counted. The cremaster muscle was exposed as described (Soehnlein et al., 2008), 
and branches of the cremasteric artery were counted. To determine capillary 
leakage, perfusion of the cremasteric artery with albumin-FITC (Sigma) was 
performed.  
 
 
III.10.6 Ischemia Hindlimb Model 
Male C57BL/6J mice were investigated in this study. They were blinded and 
randomly assigned to receive either (a) anti-MIF mAb (100 µg, i.p.) the day before 
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the ligation, (b) rmMIF (10 µg, i.p.) for five consecutive days starting one day before 
ligation, or (c) PBS. Considering published data on the effectiveness of the anti-MIF 
mAb (clone III D.9) shown to neutralize murine MIF bioactivity in vivo and in vitro 
(Garner et al., 2003) in different disease models (Calandra et al., 2000; Chagnon et 
al., 2005; Schober, 2004), I decided not to include an isotype control.  
 
The animals were first anesthetized with 5% isoflurane (flow 1-1.5 l/min) to assure a 
fast anesthesia. After the mouse is unresponsive to external stimuli, isoflurane was 
decreased to 2 - 2.5% (flow 0.3 l/min). Using an electric shaver, hair was removed 
from the limb. The mouse was placed in a supine position on the operating table and 
connected to a continuous flow of isoflurane. After skin incision was made medial on 
the right thigh, the vein and nerve were carefully dissected from the femoral artery. 
Surgical procedure was performed by ligating the right femoral, epigastric and 
popliteal artery. For analysis of perfusion recovery animals were sacrificed after 14 
days (n=6/treatment) after ligation. Animals assigned to histological evaluation and 
examination of circulating blood monocyte population were sacrificed 48 h and 24 h 
or 48 h after ligation, respectively (n=3/treatment and time point). Blood for further 
FACS analysis was drawn from the hearts and collected in EDTA tubes. For 
histological examination, abdominal aortas were cannulated. After perfusion with 
PBS, animals were rinsed with 2 ml 0.1% propidium iodide for 2 min followed by 
fixation with 100 ml PFA (4%). Samples were kept in PFA overnight, and then in 70% 
ethanol and stored at 4°C.  
 
 
III.10.7 Pre- and Post Laser Doppler Measurements 
Laser Doppler Imaging is used to assess blood perfusion in hindlimbs of mice non-
invasively and without the use of tracer dyes under standardized conditions.  
 
A laser beam detects blood cell motion from Doppler broadening of the laser light 
scattered from the skin. Thereby circulating blood in the microvasculature causes a 
shift in the Doppler frequency of the scattered laser light that is photo detected and 
subsequently processed to build up a colour coded map of blood flow. At the same 
time, a digital camera records the photograph, which corresponds closely to the 
blood flow (Essex and Byrne, 1991). This allows the comparison of blood flow in 
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hindlimbs where blood flow has been reduced by occlusion of the femoral artery, 
relative to the control hindlimb. 
 
Measurements were performed over a number of days, before, immediately after 
surgery, and on postoperative days 3, 6, 9, and 14 to assess the reperfusion 
facilitated by the development of collateral vessels. To analyse the perfusion, mean 
blood flow between the operated and non-operated hindlimbs was compared and the 
ratio for each animal was calculated (right-to-left (R/L) perfusion ratio).  
 
 
III.11 Statistical Analysis 
Data represent mean ± SEM. Statistical analysis was performed with Prism 4 
software (Graph Pad) using unpaired Student-t test or one-way analysis of variance 
(ANOVA) followed by Newmann-Keuls post hoc test, as appropriate. p-values below 
0.05 were considered statistically significant. 
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IV RESULTS 
 
IV.1 The Role of the CXCL12 / CXCR4 Axis in Experimental Myocardial 
Infarction 
Myocardial necrosis triggers complex remodeling and inflammatory changes. The 
CXCR4 receptor ligand CXCL12 has been implicated in protection and regeneration 
after myocardial infarction through recruiting angiogenic outgrowth cells, improving 
neovascularization and cardiac function. Here I assess the intrinsic functions of 
CXCR4 in remodeling after MI using CXCR4-heterozygous (CXCR4+/-) mice. 
 
 
IV.1.1 Analysis of MI Size and Inflammatory Cell Content 
Four weeks after MI, the infarct size was reduced 42% more in CXCR4+/- than in 
CXCR4+/+ littermates (8.7±1.3% vs. 14.9±1.9% of the ventricular wall; p<0.05; Figure 
11 A). Area at risk defined by TTC staining showed no difference between the two 
groups (Figure 11 B). Hence, the reduced infarct size likely reflects an enhanced 
wound contraction, rather than a difference in the initial extent of cardiomyocyte 
injury. Moreover, the myofibroblast infiltration (2,600±283 vs. 1,011±165/mm² in 
controls, p<0.001) and collagen content in the infarcted area was significantly higher 
in CXCR4+/- mice than in wild-type controls (p<0.05; Figure 11 C), indicating a more 
stable and robust scar formation.  
 
 
Figure 11: Analysis of myocardial infarction (MI). Compared to wild-type mice, CXCR4+/- 
mice display a significantly smaller infarct size (A) but no differences in the area at risk one 
day after MI (B), and a significant increase in myocardial collagen content (C, scale bar 50 
µm) 4 weeks after MI, (*p<0.05 vs. wild-type). 
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Next, I analyzed the mobilization and recruitment of inflammatory cells after MI. The 
MI-induced and transient expansion of neutrophils in the circulation (Figure 12 A) and 
infiltration of the infarcted area with neutrophils (Figure 12 B) was severely reduced in 
CXCR4+/- mice 1 day after MI. This shows that the initial inflammatory response 
differed markedly in CXCR4+/- mice, indicating a prominent role of CXCR4 in post-
infarction neutrophil recruitment. Further, while no difference in peripheral blood 
monocyte levels between conditions was apparent after MI (Figure 12 C), the 
myocardial infiltration with monocytes/macrophages was diminished 4 days after MI 
in CXCR4+/- compared to wild-type mice, but subsequently increased resulting in a 
higher myocardial macrophage content at 14 days after MI (Figure 12 D, E).  
 
 
 
 
Figure 12: Analysis of inflammatory cells after myocardial infarction (MI). Neutrophil 
counts in peripheral blood as analyzed by flow cytometry (A), as well as neutrophil infiltration 
in myocardium, as analyzed by immunofluorescence (B, scale bar 50 µm) are reduced in 
CXCR4+/- versus wild-type mice after MI. No differences were observed in total monocyte 
counts in peripheral blood (C), whereas myocardial infiltration with monocytes/macrophages 
was delayed and enhanced at later stages in CXCR4+/- versus wild-type mice (D, E, scale bar 
50 µm) (*p<0.05 vs. wild-type).  
 
 
 
RESULTS 
54 
Analysis of monocyte subsets revealed a reduced number of circulating Gr-1high cells 
and relative expansion of Gr-1low cells and subsequently lower Gr-1high/Gr-1low ratio in 
peripheral blood of CXCR4+/- after MI (Figure 13 C). These data correspond to 
diminished infiltration with proinflammatory tissue-degrading Gr-1high monocytes 4 
days after MI, whereas Gr-1low monocytes, known to promote wound healing and 
collagen deposition (Nahrendorf et al., 2007), were increased in the hearts of 
CXCR4+/- (Figure 13 D). Thus, the inflammatory reaction after MI in CXCR4+/- mice is 
shifted to an earlier termination of the acute response and onset of a repair process 
involving Gr-1low monocytes. Notably, whereas CXCR4 expression on Gr-1low 
monocytes from CXCR4+/- mice (specific mean fluorescence intensity/sMFI 31.5±3.0) 
was reduced by 43%, as compared to Gr-1low monocytes from wild-type mice (sMFI 
61.9±7.4) (Figure 13 A), the low CXRC4 expression on Gr-1high monocytes did not 
differ between both genotypes (sMFI 6.8±3.5 vs. 5.2±1.5) (Figure 13 B). This 
suggests a strong adaptation of Gr-1low cells to reduced CXCR4 expression and a 
possible role of other receptors in their recruitment.  
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Figure 13: Analysis of Gr-1low / Gr-1high monocytes after myocardial infarction.  
Flow cytometry analysis after MI of CXCR4 expression on Gr-1low (A) and Gr-1high (B) 
demonstrated a reduced expression of CXCR4 on Gr-1low monocytes from CXCR4+/- 
compared to wild-type mice (*p<0.05 vs. wild-type), whereas the already low expression of 
CXCR4 on Gr-1high monocytes did not differ between the groups. The Gr-1high / Gr-1low ratio 
showed a reduction of Gr-1high cells over time and an expansion of Gr-1low cells in peripheral 
blood of CXCR4+/- versus wild-type mice, representing a relative shift towards Gr-1low cells 
(C). Analysis of the myocardial infiltration revealed a transient but marked reversal of the Gr-
1high / Gr-1low ratio at day 1 after MI in both groups (D) and an earlier return to baseline levels 
with increased at day 4 with increased infiltration of Gr-1low cells in CXCR4+/- versus wild-type 
mice. (*p<0.05 vs. wild-type). 
 
 
IV.1.2 Analysis of Cardiac Function after MI 
Echocardiography (Table 3) and Langendorff (Table 4) measurements surprisingly 
failed to reveal changes in ventricular function, in particular no improvement of 
contractility, after MI in CXCR4+/- versus wild-type mice was found. However, I 
observed a slightly decreased baseline ejection fraction, as well as a moderate 
increase in the post-MI ejection fraction in CXCR4+/- mice compared with wild-type 
mice (Table 3). Moreover, the difference in ejection fraction before and after MI was 
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significantly decreased in CXCR4+/- mice compared with wild-type (7.6±1.2% vs. 
16.8±2.4%, p<0.01), implying a protective or adaptive mechanism in CXCR4+/- 
hearts.  
 
 
Table 3: Echocardiography parameters in wild-type and CXCR4+/- mice (LV - left 
ventricle) 
Echocardiography 
Parameter 
Before MI 4 weeks after MI 
wild-type CXCR4+/- wild-type CXCR4+/- 
 n=6-9 N=7-10 n=6 n=7 
Heart weight (mg) 128 ± 28 114 ± 35 150 ± 52 153 ± 17 
Heart rate (bpm) 476± 66 464 ± 31 442 ± 26 510 ± 37 
Respiration rate (bpm) 122 ± 40 116 ± 32 144 ± 26 156 ± 64 
Cardiac output (ml/min) 22.1 ± 5.7 18.4 ± 3.8 19.1 ± 3.2 20.3 ± 6.2 
Stroke volume (µl) 41.7 ± 9.4 39.3 ± 9.0 40.2 ± 6.8 40.2 ± 10.9 
Ejection fraction (%) 74.7 ± 2.0 69.8 ± 9.6 54.8 ± 8.2 63.9 ± 11.0 
Fractional shortening (%) 42.8 ± 2.3 39.3 ± 7.5 31.5 ± 4.3 34.7 ± 5.6 
LV diameter; d (mm) 3.4 ± 0.8 3.4 ± 0.3 4.2 ± 0.4 4.1 ± 0.6 
LV diameter; s (mm) 2.0 ± 0.9 1.9 ± 0.3 2.9 ± 0.3 2.7 ± 0.7 
 
 
Table 4: Functional parameters of wild-type and CXCR4+/- hearts. (LVDP - left ventricular 
developed pressure; dPdt - derivative of pressure increase (max) and decay (min); *p<0.05 
vs. wild-type.)  
Langendorff perfusion 
Parameter 
Before MI 4 weeks after MI 
wild-type CXCR4+/- wild-type CXCR4+/- 
 n=3-4 n=3-5 n=4-5 n=5-6 
LVPD (mmHg) 
increase after Dobutamin (∆) 
86.7 ± 8.8 
40.3 ± 4.0 
78.3 ± 17.0 
46.2 ± 5.2 
40.0 ± 10.1 
13.8 ± 4.3 
50.0 ± 11.5 
10.3 ± 2.6 
dPdt max (mmHg/sec) 
increase after Dobutamin (∆) 
3189 ± 99 
 2410 ± 629 
3058 ± 363 
1941 ± 187 
1540 ± 97 
770 ± 91 
1590 ± 94 
 704 ± 74 
dPdt min (mmHg/sec) 
increase after Dobutamin (∆) 
-2695 ± 244 
-1756 ± 544 
-2011 ± 411  
-1407 ± 314 
-1267 ± 111 
545 ± 28 
-1280 ± 79 
484 ± 68 
Coronary flow (ml) 
Increase after short ischemia (∆) 
3.9 ± 0.2 
3.4 ± 0.2 
2.0 ± 0.3* 
2.8 ± 0.1* 
3.2 ± 0.3 
1.8 ± 0.4 
1.2 ± 0.3* 
0.2 ± 0.1* 
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Moreover, coronary perfusion was markedly diminished in CXCR4+/- versus wild-type 
mice, as determined by coronary flow measurements in isolated perfused hearts. 
Coronary flow was already reduced under baseline conditions (p<0.01; Table 4, 
Figure 14 A). Ligation of the LAD decreased coronary flow by approximately 50% in 
both groups after one day, demonstrating an equivalent area of risk in CXCR4+/- and 
wild-type mice (Figure 14 A, B). Four weeks after MI, the recovery of coronary 
perfusion was significantly impaired in CXCR4+/- mice, resulting in a reduced flow 
rate of 1.2±0.3 ml/min compared with 3.2±0.3 ml/min in wild-type mice (p<0.05; Table 
4, Figure 14 A, B).  
 
To assess whether defective cardiac angiogenesis and neovascularization after MI 
contributes to these differences in coronary blood flow, myocardial endothelial cells 
and vessels were quantified. As determined by flow cytometry, the number of 
myocardial endothelial cells was intrinsically reduced in CXCR4+/- versus wild-type 
mice (0.60±0.04% vs. 2.04±0.30% CD31+ KDR/VEGF-R2+ cells, p<0.05, Figure 14 
C). Similarly, neovascularization after MI was impaired in CXCR4+/-, as evident by 
reduced formation of CD31+ blood vessels in infarcted myocardium (p<0.05, Figure 
14 D). This reduction might contribute to the defective recovery of coronary flow after 
MI in CXCR4+/- mice. Moreover, the number of primary branches of coronary arteries 
(56.7±5.2 vs. 30.0±6.9, p<0.05, Figure 14 E) as shown by Micro-Angio-CT, as well as 
epicardial coronary veins, and the number of cremasteric artery branches as 
quantified by intravital microscopy was diminished in CXCR4+/- versus wild-type mice 
without evidence for disturbed endothelial permeability, as showed by perfusion of 
the cremasteric artery with albumin-FITC. This indicates that the endogenous defect 
in angiogenesis was not restricted to the heart.  
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Figure 14: Analysis of coronary flow and angiogenesis. Langendorff perfusion revealed a 
reduction of coronary flow in CXCR4+/- versus wild-type mice both at basal conditions and 4 
weeks after MI (A). Despite equivalent flow reduction after MI, recovery of coronary flow after 
MI, represented as percentage of basal coronary flow, was impaired in CXCR4+/- versus wild-
type mice 4 weeks after MI (B). Flow cytometry analysis indicated a decreased number of 
endothelial cells in myocardial tissue, as determined by co-staining for CD31 and KDR (C). 
Immunohistochemical analysis of the MI area at different time points after MI confirmed the 
impairment in neo-angiogenesis, as assessed by the density of vessels stained CD31 in 
CXCR4+/- versus wild-type mice (D, scale bar 50 µm). The quantification of the branches of 
the coronary artery (E) showed a marked impairment of vessel density in CXCR4+/- versus 
wild-type mice under basal conditions (red arrows show left anterior descending and 
circumflex arteries). (* p<0.05 vs. wild-type).  
 
 
To distinguish the influence of the CXCR4 heterozygous background and its role in 
circulating cells, bone marrow chimera experiments were performed after lethal 
irradiation. The next day, I reconstituted wild-type mice with CXCR4+/- bone marrow, 
CXCR4+/- mice with wild-type bone marrow, and wild-type mice with wild-type bone 
marrow (control). Six weeks later, MI was induced and after another four weeks, the 
infarction area was significantly reduced in wild-type mice transplanted with CXCR4+/- 
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bone marrow and in CXCR4+/- mice transplanted with wild-type bone marrow 
compared with control group (14.5±2.2 and 16.2±4.2, vs. 20.8±0.8, p<0.05, Figure 15 
A). Besides effects attributable to reduced leukocyte infiltration, these data suggest 
the existence of an additional intrinsic mechanism, which can substantially influence 
scar formation in our model. Notably, neovascularization after MI was impaired in 
both groups (wild-types transplanted with CXCR4+/- bone marrow and CXCR4+/- mice 
transplanted with wild-type bone marrow) compared with controls, as evident by 
CD31+ staining in infarcted myocardium (856±73 vessels/mm² and 527±43 
vessles/mm² and 1046±73 vessels/mm² in control, respectively, p<0.05 vs. control, 
Figure 15 B). Whereas heart function, as assessed by echocardiography (ejection 
fraction) and Langendorff perfusion (left ventricular developed pressure) showed no 
significant differences between the groups (Figure 15 C). The reduction of 
neovascularization was more pronounced in CXCR4+/- mice transplanted with wild-
type bone marrow and correlated with decreased coronary flow as evident by 
Langendorff perfusion of isolated hearts (Figure 15 D). This may reflect that the 
vascularization of the scar is based mostly on vessel formation around pre-existing 
collaterals, which may explain the markedly reduced neovascularization in CXCR4+/- 
mice despite reconstitution with wild-type bone marrow.  
 
The myocardial infiltration with neutrophils and monocytes, as well as blood 
leukocyte subsets (Figure 15 E) after MI did not differ between wild-type and 
CXCR4+/- mice transplanted with wild-type bone marrow but were significantly 
reduced in wild-type mice transplanted with CXCR4+/- bone marrow, thus emulating 
the pattern in CXCR4+/- mice and indicating a shift towards an earlier termination of 
the acute response and earlier onset of a repair process.  
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Figure 15: Effect of CXCR4 deficiency in bone marrow cells after myocardial infarction 
(MI). Four weeks after MI, the infarction area (A) and neovascularization, as evident by 
CD31+ staining in infarcted myocardium (B, scale bar 50 µm), was reduced in wild-type mice 
transplanted with CXCR4+/- bone marrow and in CXCR4+/- mice transplanted with wild-type 
bone marrow, as compared to wild-type controls transplanted with wild-type bone marrow. 
Ejection fraction, as assessed by echocardiography, and left ventricular developed pressure, 
as assessed by Langendorff perfusion, were unaltered (C). Coronary flow, as determined by 
Langendorff perfusion of isolated hearts revealed reduced perfusion in wild-type mice 
transplanted with CXCR4+/- bone marrow and in CXCR4+/- mice transplanted with wild-type 
bone marrow compared with control (D). As analyzed by flow cytometry, blood leukocyte 
subsets counts in peripheral blood after MI did not differ between CXCR4+/- mice and wild-
type mice reconstituted with wild-type bone marrow, whereas wild-type mice reconstituted 
with CXCR4+/- bone marrow showed a reduction in blood neutrophils and Gr-1high / Gr-1low 
ratio (E), representing a relative shift towards Gr-1low cells, similarly as observed in CXCR4+/- 
mice. (*p<0.05 vs. wild-type mice reconstituted with wild-type bone marrow). 
 
 
IV.1.3 The Role of CXCR4 for EPC Trafficking and Function 
Since EPCs contribute to post-infarction neo-angiogenesis, I studied the effect of 
CXCR4 on EPC function. Notably, spleen derived murine CXCR4+/- and wild-type 
EPCs were analyzed by flow cytometry after culturing for 10 days. Both exhibit 
endothelial-like properties, namely acLDL uptake, binding of lectin (Figure 16 A), VE-
cadherin and von Willebrand factor mRNA expression (Figure 16 B) and surface 
expression of CD31 and VEGF-R2 (Figure 16 C). Despite this endothelial phenotype, 
the function of CXCR4+/- EPCs was impaired. In chemotaxis assays, the migration of 
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EPCs from CXCR4+/- versus wild-type mice towards CXCL12 (but not towards VEGF) 
was significantly reduced (Figure 16 D). Moreover, endothelial tube formation by 
CXCR4+/- versus wild-type EPCs in vitro (Figure 16 F) and vessel infiltration in 
subcutaneously implanted Matrigel plugs in CXCR4+/- versus wild-type mice (Figure 
16 G) were significantly attenuated.  
 
 
 
Figure 16: The role of CXCR4- in trafficking and function of angiogenic outgrowth 
cells. Endothelial progenitor cells (EPCs) isolated from spleens of CXCR4+/- or wild-type 
mice exhibit endothelial cell-like properties after culture for 10 days, e.g. acLDL up-take, 
binding of lectin (A), vWF and VE-cadherin mRNA expression, as assessed by quantitative 
RT-PCR (B), and surface expression of CD31 and VEGF-R2, as analyzed by flow cytometry 
(C). In chemotaxis assays, CXCR4+/- EPCs showed deficient migration towards CXCL12 but 
not VEGF as compared to wild-type EPCs (D). Tube formation by CXCR4+/- or wild-type 
EPCs on matrigel in vitro (F) and neo-angiogenesis in subcutaneously implanted matrigel in 
vivo (G, scale bar 50 µm) were both significantly impaired. (*p<0.05 vs. wild-type). 
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Compared to wild-type mice, CXCL12 mRNA expression was increased in uninjured 
myocardium of CXCR4+/- mice, possibly reflecting compensatory induction due to 
reduced vascularization, but its up-regulation after MI was not affected in CXCR4+/- 
mice (Figure 17 A), indicating that differences in myocardial endothelial cell content 
and vessel density are rather attributable to defective recruitment of EPCs. No 
differences were observed in VEGF mRNA expression in CXCR4+/- and wild-type 
mice, before or after induction of MI.  
 
 
IV.1.4 Myocardial Apoptosis after Myocardial Infarction 
Given the unaltered cardiac function despite the reduced basal myocardial 
vascularization in CXCR4+/- compared with wild-type mice, I tested whether 
cardiomyocyte survival and proliferation were affected. The myocardial mRNA 
expression of Bax (pro-apoptotic marker) and Bcl2 (anti-apoptotic marker) was 
studied by RT-PCR in uninjured hearts. No difference in Bax and Bcl2 expression 
was observed between CXCR4+/- and wild-type mice (Figure 17 B). Myocardial 
apoptosis after induction of MI was slightly decreased 4 days but not 7 or 14 days 
after MI in CXCR4+/- compared to wild-type mice, as assessed by quantifying 
TUNEL+ cells (Figure 17 C). These data indicate a possible adaptive mechanism of 
CXCR4+/- cardiomyocytes to the reduced oxygen supply. 
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Figure 17: Myocardial apoptosis after myocardial infarction (MI). Expression of CXCL12 
mRNA was increased in uninjured myocardium of CXCR4+/- mice but it’s up-regulation after 
MI was not affected in CXCR4+/- mice (A), as shown by RT-PCR. Moreover, no differences in 
myocardial Bax and Bcl2 mRNA expression were observed in CXCR4+/- versus wild-type, as 
assessed by RT-PCR from uninjured hearts (B). Myocardial apoptosis assessed by TUNEL  
staining at different time points after MI showed reduced apoptosis in CXCR4+/- versus wild-
type 4 day after MI, and  no differences at later time-points (C, scale bar 50 µm, *p<0.05 vs. 
wild-type). 
 
 
IV.1.5 Electron Microscopy and Characterization of Lipid Extracts 
To detect structural cellular alterations, I performed electron microscopy in CXCR4+/- 
and wild-type hearts before or 1 day after MI. Wild-type myocardium displayed 
extensive signs of necrosis with dramatic structural changes and cellular 
disintegration (Figure 18 A). In infarcted CXCR4+/- myocardium, signs of myofibril 
disorganization and cardiomyocyte swelling were present but cellular structures were 
still distinguishable (Figure 18 A). Notably, atypical lipofuscin-like lipid accumulations 
were found in uninjured CXCR4+/- myocardium with strong osmium tetroxide fixation 
(Figure 18 A). Such lipid accumulations have been described after dietary fish oil 
feeding, containing long-chain monounsaturated fatty acids and a degraded form of 
peroxidized lipids, and have been associated with reduced ischemic damage in rat 
hearts (Nalbone et al., 1988; Yang et al., 1993).  
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Subsequent lipid extraction and HPLC analysis indicated a marked accumulation of 
phosphatidylserine (PS, fractions 1-3) in CXCR4+/- hearts, which was absent in wild-
type hearts (Figure 18 B). Using gas chromatography, I analyzed the unsaturated 
fatty acid index of cardiac lipid extracts (triglyceride, phosphatydilcholine/-
ethanolamine, PS). The triglyceride fraction (TG) obtained from CXCR4+/- hearts 
contained 10% more unsaturated fatty acids than wild-type hearts, and six different 
unsaturated fatty acids appeared in TG of CXCR4+/- hearts, namely C16:1, C18:3n6, 
C20:1, C20:3n6, C22:1n9 and C22:2. No differences were noted for 
saturated/unsaturated fatty acid content in phosphatydilcholine or -ethanolamine. The 
fatty acid composition of the three PS fractions is detailed in Table 5. 
 
 
 Saturation (%) Fatty acids (%) 
 
 
 
 
PS 1  
Saturated          59.8 C14:0        25.7  
C16:0  10.5 
C18:0  14.3 
C22:0  9.3 
Unsaturated      26.4 C18:1n9c 4.2 
C18:2c  5.5 
C18:3n6 3.9 
C20:4n6 11.5 
C22:6n3 11.4 
 
 
 
PS 2 
Saturated          47.2 C16:0        13.8 
C18:0  23.0 
C22:0  10.4 
Unsaturated      42.5 C18:1n9c 12.0 
C18:2c            7.7 
C22:6n3 22.8 
 
 
 
 
 
 
PS 3 
Saturated          19.0 C16:0  4.3 
C18:0  8.4 
C22:0  6.3 
Unsaturated      76.9 C14:1        1.8 
C16:1  4.7 
C18:1n11c 11.6 
C18:2c   11.2 
C18:3n6 9.5 
C20:1  11.3 
C20:3n6 9.5 
C22:1n9 3.0 
C22:2  4.6 
C22:6n3 9.2 
 
Table 5: Fatty acid composition of PS fractions from CXCR4+/- hearts. 
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To evaluate a potential contribution of the PS fractions to cardioprotection in 
CXCR4+/- mice, isolated cardiomyocytes were pre-incubated with the PS fractions 1, 
2 or 3 for 3 hours and the response to hypoxic stress was analyzed. As evident by 
DHE staining to monitor radical formation, all PS fractions protected cardiomyocytes 
against hypoxic injury (Figure 18 C). Notably, PS fraction 1 with the highest 
percentage of saturated fatty acids offered the best protection to hypoxic injury. 
These data indicate that CXCR4+/- hearts could be intrinsically adapted to hypoxic 
injury, together with an attenuated inflammatory response explaining the smaller MI 
size despite impaired neovascularization. 
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Figure 18: Myocardial electron microscopy and characterization of lipid extracts.  
Electron microscopy showed atypical lipofuscin-like lipid accumulation with a strong osmium 
fixation (A, left side, one representative lipid vesicle in insert). After MI, CXCR4+/- 
myocardium exhibits signs of myofibril disorganization and cardiomyocyte swelling but still 
distinguishable cellular structures, whereas wild-type myocardium shows signs of necrosis 
with dramatic structural disintegration (A, right side). Lipid extraction and HPLC analysis 
indicates, beside the triglyceride (TG, first peak), phosphatydilethanolamine (PE, second 
peak) and phosphatydilcholine (PC, third peak), an up-regulation of the phosphatidylserine 
(PS) in CXCR4+/- hearts, which is not present in wild-type hearts (B). In vitro hypoxia 
experiments, pre-incubation of isolated cardiomyocytes with PS fractions protects against 
hypoxic injury, as shown by DHE staining (C, *p<0.01 vs. control, §p<0.05 vs. ischemia, 
n=4). 
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IV.2 MIF-induced Angiogenic Potential of EPCs 
Stem cell-induced angiogenesis, including the use of endothelial progenitor cells, as 
a process of neovascularization has obtained great interest for treating 
cardiovascular ischemic diseases. Angiogenesis is a highly regulated complex 
process depending on a cocktail of factors and involving multiple steps. MIF, but also 
VEGF, CXCL12 and CXCL1 are likely involved in this process. To better understand 
the behavior of EPCs in response to different growth factors, I evaluated the 
angiogenic potential of these different factors; associated with the function of EPCs in 
angiogenesis.  
 
 
IV.2.1 Characterization of Spleen-derived EPCs 
Flow cytometry analysis of spleen-isolated EPCs revealed combined expression of 
endothelial (CD31, VEGFR-2) and myeloid cell markers (CD11b) (IV.1.3). 
Furthermore, CXCR2 and CXCR4 were present on the cell surface of these cells 
(Figure 19), whereas CD74, which can bind MIF and potentially functions as a co-
receptor for CXCR2 and CXCR4, was not expressed. 
 
 
 
 
Figure 19: Characterization of spleen-derived EPCs. The expression of CXCR2 and 
CXCR4 was assessd in spleen-derived EPCs by flow cytometry; representative histograms 
are shown, unstained cells served as control (grey graph). 
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IV.2.2 In vitro Chemotaxis and Transmigration of EPCs 
Chemotaxis assay was performed in a 24-well cell culture chamber. EPCs were 
added into the membrane inserts. The culture chamber contained assay medium only 
as control or enriched with different chemokines/cytokines in the lower chamber 
which served as chemoattractants for these cells. Chemotaxis experiment showed 
that EPCs migrate through the filter over 2 hstimulation time. The potential of EPCs 
to migrate was multiplied towards chemokine/cytokine stimulation compared to 
unstimulated cells (assay medium only). rmVEGF and rmMIF increased fivefold and 
fourfold the chemoattraction of EPCs compared to control, respectively. The 
chemotactic effect of rmCXCL12 and rmCXCL1 has tripled compared to control 
(Figure 20 A, p<0.05 vs. control). In contrast to the chemotaxis assay, the 
transmigration assay was performed using an additional SVECs monolayer on the 
surface of the filter membrane. The transmigration capacity of EPCs over this 
endothelial monolayer was examined using a modified Boyden chamber. In contrast 
to the effect of the stimuli rmVEGF, rmMIF, rmCXCL12 and rmCXCL1 on EPC 
chemotaxis, transmigration was highest for MIF, inducing transmigration 2.6-fold. 
This was followed by rmCXCL1 with a significant lower number 1.7-fold to higher 
than control (Figure 20 B, p<0.05 vs. control). Contrary to the chemotaxic assay, 
rmCXCL12 and rmVEGF presented with transmigration capacity compared to control 
(Figure 20 B). These data demonstrate that rmMIF is a potent trigger for chemotaxis 
and transmigration of EPCs. 
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Figure 20: The role of chemokines and growth factor in EPC recruitment. rmMIF, 
rmVEGF, rmCXCL12 and rmCXCL1 enhance the chemotactic potential of EPCs to migrate 
through the filter (A). EPCs transmigration over an additional monolayer of SVECs was 
enhanced after stimulation with rmMIF and rmCXCL1, whereas rmVEGF and rmCXCL12 
failed to increase these capacity (B). For statistical analysis, controls were set at 1 and the 
experimental groups were normalized to 1 (*p<0.05 vs. control, n=3). 
 
 
IV.2.3 Tube Formation Potential of EPCs in vitro 
To study the angiogenic potential of rmMIF, rmVEGF, rmCXCL12 and rmCXCL1 on 
tube formation capacity of EPCs, matrigel experiments were performed. EPCs on the 
matrigel alone showed no capability to form tube-like structures. Therefore, co-culture 
of EPCs and SVECs were used and placed together on matrigel basement. After 
incubation for 24 h, sprouting of SVECs was enhanced. All test factors significantly 
increased the integration of EPCs and the formation of tube-like structures on the 
matrigel in vitro (Figure 21 A). Thereby rmCXCL12 and rmCXCL1 showed the 
highest potential to form tubes followed by rmVEGF and rmMIF compared to control 
(12.5 +/- 0.95 > 12.0 +/- 1.3 > 11.4 +/- 0.67 > 9.0 +/- 0.54 vs. control 4.3 +/- 0.66, 
respectively, p<0.05 vs. control). In figure 21 B, representative pictures show the 
alterations in tube forming potential of EPCs according to the added test factors. 
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Figure 21: Effect of stimulation on EPC-SVEC tube formation. Number of formed tubes 
on matrigel by co-culture of EPCs and SVECs after 24 h in vitro triggered by rmMIF, 
rmVEGF, rmCXCL12 and rmCXCL1 (*p<0.05 vs. control, n=6) (A). Representative pictures 
show the tube formation by all test factors on matrigel in vitro (B).  
 
 
IV.3 The Role of Macrophage Migration Inhibitory Factor in Collateral 
Formation 
The importance of leukocytes in collateral artery growth (arteriogenesis) has been 
recognized. Proper recruitment of monocytes and their differentiation into 
macrophages are indispensable for arteriogenesis. Macrophage migration inhibitory 
factor (MIF) known as an inflammatory cytokine with chemokine-like functions has 
been associated with macrophage function related to atherogenesis and 
angiogenesis. Here, I assess the effect of MIF in collateral formation.  
 
 
IV.3.1 Analysis of Collateral Growth and Inflammatory Cell Content 
To determine whether MIF can affect arteriogenesis, paw reperfusion was examined 
in a murine ischemic hindlimb model as a reflection of collateral remodeling. 
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Reperfusion of ischemic hindlimb in mice treated with saline (control, CTL), 
recombinant murine MIF (rmMIF), or anti-MIF murine antibody (anti-MIF mAb) was 
measured by Laser Doppler imaging at day 3, 6, 9, and 14 after ligation.  
 
All treated mice showed perfusion recovery of the occluded hindlimb although 
differences in reperfusion were apparent (Figure 22 A). At all time points analyzed 
rmMIF-treated mice showed depressed perfusion rates in comparison to CTL, 
whereas the anti-MIF group presented the opposite effect (increased recovery). 
Significant differences (relative rates) in perfusion rate were apparent between anti-
MIF and rmMIF groups at day 6 (0.49+/-0.04 vs. 0.39+/-0.02, p<0.05), day 9 (0.55+/-
0.03 vs. 0.42 +/-0.03, p<0.05) and day 14 post-ligation (0.55+/-0.02 vs. 0.37+/-0.4, 
p<0.05). Furthermore, anti-MIF mAb treatment increased reperfusion compared to 
control but did not reach significance. Comparing rmMIF with control, reperfusion was 
diminished after rmMIF treatment. Significant differences were observed at day 14 
between groups (0.37+/-0.04 vs. 0.5+/-0.02, p<0.05) (Figure 22 A, B). 
 
 
 
Figure 22: Analysis of Collateral Growth. (A) Reperfusion data of the ligated hindlimb 
presented as ratio of hindlimb perfusion right (ligated) to left (non-ligated). Anti-MIF mAb 
treatment enhanced reperfusion, whilst rmMIF decreased reperfusion. At day 6, 9 and 14, 
significant differences were observed between the anti-MIF mAb and rmMIF group (#p<0.05 
vs. rmMIF) and at day 14 between the rmMIF and control group (*p<0.05 vs. control) (B) 
Representative Laser Doppler Images of the experimental groups at day 9 and 14 post 
ligation. Blue indicating minimal and red maximal perfusion. Mice treated with anti-MIF mAb 
or CTL showed clear recovery of perfusion for the ligated paw (area 2). Recovery in the 
rmMIF group was much lower at both day 9 and 14 compared with both anti-MIF and CTL 
group, as reflected by lower perfusion rate of the ligated paw in the rmMIF group. 
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Considering published data, macrophages express high levels of CXCR2 (Baggiolini, 
1998; Boisvert et al., 1998; Patterson et al., 2002). CXCR2/Mac2 double staining 
showed that macrophages in the ischemic skeletal muscle express CXCR2. The 
immunohistochemical stainings of ischemic skeletal muscle tissue at day 2 post-
ligation for macrophages (Mac2) and functional MIF receptor CXCR2 illustrated that 
CXCR2 was at a significantly lower level in the rmMIF group compared to the anti-
MIF group (13,69±1,25 cells/field vs. 36,16±1,8 cells/field) (Figure 23 A). Also Mac2 
staining revealed a similar tendency in the rmMIF group with a lower amount of 
macrophages being present in hindlimb tissue as compared with control (16.54±0.69 
cells/field vs. 36.25±1.68 cells/field in controls), whereas a significant higher amount 
was found in the anti-MIF group (44.81±2.49 cells/field) (Figure 23 B). CD74 
expression in the ischemic skeletal muscle increased after both treatments (rmMIF 
15.80+/-1.1, anti-MIF 33.35+/-2.55, ctr 9.33+/-0.71) but doubled after anti-MIF mAb 
treatment compared to rmMIF treatment (Figure 23 C). CXCR4 and MIF staining in 
the skeletal muscle, expressed as pixel per field (CXCR4 staining: rmMIF 1468+/-
2.13 > anti-MIF 968.8+/-99.62 > ctr 388.3+/-57.33) and percentage of positive tissue 
(MIF staining: rmMIF 42.60+/-2.35 > anti-MIF 33.71+/-2.71 > ctr 14.61+/-2.13), 
respectively, showed an increase after both treatments with a higher amount in 
rmMIF treated compared to anti-MIF mAb treated mice (Figure 23 D, E). 
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Figure 23: Immunohistochemical stainings of the ischemic skeletal muscle 48 h after 
ligation for macrophages, MIF and its receptors. rmMIF diminished, whereas anti-MIF 
mAb increased the number of CXCR2-positive cells (A) and macrophages (B) in the 
ischemic skeletal muscle (*p<0.05 vs. control). Violet (A) and red (B) dots indicating the 
positive stained cells. (C) CD74 expression as percentage of total cell surface increased in 
both treatments, but doubled after anti-MIF mAb treatment (*p<0.05 vs. control). Staining for 
CXCR4 (D) and MIF (E) in skeletal muscle revealed an increase in both groups, with a higher 
level in the rmMIF group (*p<0.05 vs. control).  
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IV.3.2 The Role of MIF in Macrophage Polarization 
As differences in arteriogenesis for the rmMIF group can relate to altered 
macrophage polarization, we tested the effect of rmMIF on polarization of mice bone 
marrow-derived macrophages (BMM). Bone marrow-derived monocytes were 
isolated and cultured over 8 days while they differentiated into macrophages. These 
cells were stimulated with different concentrations of rmMIF. Within this context M1 
macrophages are considered pro-inflammatory whereas M2 macrophages are pro-
angiogenic. In contrast with classical inducers of macrophage polarization INF-γ (M1) 
and IL-10, but also IL4 and IL13 (M2), rmMIF stimulation had no clear effect on 
polarization neither to M1 (TNF-α) nor to M2 (IL-19, YM-1) macrophages in this 
setting (Figure 24), but decreased CXCR2 expression of BMM on mRNA level 
(Figure 25 A). CXCR4 mRNA content depended on the used rmMIF concentrations. 
The expression level was increased for 5, 400 and 500 ng/ml rmMIF stimulation, but 
decreased after stimulation with 10, 50 and 200 ng/ml, reflecting a biphasic effect of 
rmMIF stimulation on these cells (Figure 25 B). MIF mRNA content was significantly 
increased after stimulation with 5, 100, 400 and 50 ng/ml, but decreased with 10 
ng/ml (Figure 25 C). Only stimulation with 5 and 200 ng/ml rmMIF raised significantly 
the mRNA expression of CD74 (Figure 25 D).  
 
 
 
Figure 24: Expression of M1 (TNF-α) and M2 (IL-10, YM-1) markers after MIF 
stimulation. Bone marrow derived macrophages were stimulated with different rmMIF 
concentrations. After 24 hours, the mRNA was isolated and gene expression was assessed 
by real-time PCR analysis. 
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Figure 25: Analysis of mRNA expression of CXCR2, CXCR4, MIF and its receptor CD74 
in BMMs after rmMIF stimulation. Cultured bone marrow-derived monocytes that 
differentiated into macrophages were stimulated with different rmMIF concentrations. RT-
qPCR defined expression levels of CXCR2 (A), CXCR4 (B), MIF (C) and CD74 (D) (*p<0.05 
vs. control, n=3). 
 
 
IV.3.3 Analysis of Circulating Blood Monocytes 
Flow cytometry analysis of circulating blood monocytes at 24 and 48 h post hindlimb 
ischemia revealed differences in monocyte subpopulations for groups treated with 
rmMIF and anti-MIF mAb. Blocking MIF resulted in an increase of CD11b+ 
monocytes, whilst rmMIF reduced the level of these circulating cells (Figure 26 A). In 
all three groups, the number of circulating Ly6Chigh monocytes were raised after 48 h 
compared to 24 h after ligation. The level of Ly6Chigh monocytes did not differ 
between rmMIF-treated and control mice neither after 24 nor after 48 h. The number 
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of Ly6Chigh monocytes was significantly reduced in the anti-MIF group after 24 h, 
which almost doubled after 48 h reaching content of 71% of all CD11b+ monocytes. 
In contrast, only anti-MIF mAb-treated mice showed an increased of Ly6Clow 
monocyte content after 24 h, followed by an substantial drop to levels comparable in 
rmMIF and control, which did not show altered Ly6Clow monocytes numbers neither 
after 24 nor after 48 h (Figure 26 C). Similar results were found for circulating 
CXCR2+ monocytes after anti-MIF mAb treatment. Anti-MIF mAb namely enhanced 
the number of CXCR2+ monocytes after 24 h and reduced it after 48 h. All three 
treatments showed a decrease in the number of circulating CXCR2+ monocytes after 
48 h when compared with 24 h after ligation (Figure 26 B). Blocking MIF resulted in a 
higher level of circulating blood monocytes, particularly in an increase of CXCR2+ 
and the pro-arteriogenic Ly6Clow monocytes after 24 h. 
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Figure 26: Analysis of circulating blood monocytes after hindlimb ischemia. The 
number of CD11b+ monocytes in peripheral blood as analyzed by flow cytometry were 
reduced after rmMIF treatment, whereas blocking endogenous MIF enhanced the number of 
CD11+ monocytes (*p<0.05 vs. control) (A). After 24 h, CXCR2+ monocytes are not 
significantly reduced after rmMIF, but almost tripled after anti-MIF mAb treatment compared 
to rmMIF (*p<0.05 vs. control, #p<0.05 vs. 24 h rmMIF) and returned to lower levels after 48 
h (§p<0.05 vs. 24 h anti-MIF mAb) (B). No differences between the rmMIF and control group 
were observed in Ly6Chigh and Ly6Clow monocytes, neither 24 h nor 48 h after ligation. 
Ly6Chigh monocytes were reduced after 24 h (*p<0.05 vs. control, #p<0.05 vs. 24 h rmMIF) 
and doubled after 48 h (*p<0.05 vs. control, #p<0.05 vs. 48 h rmMIF, §p<0.05 vs. 24 h anti-
MIF mAb). Flow cytometry analysis showed further a strong increase in Ly6Clow monocytes 
after anti-MIF mAb treatment (*p<0.05 vs. control, #p<0.05 vs. 24 h rmMIF) with a drop to the 
levels of rmMIF and control group (§p<0.05 vs. 24 h anti-MIF mAb) (C). 
 
RESULTS 
78 
IV.3.4 Adhesion and Transmigration of Monocytes in vitro  
To analyze the effect of rmMIF on the adhesion of monocytes to an endothelial layer, 
I performed static adhesion experiments. After 24 h, SVECs form an endothelial 
monolayer on 96-well plates. Calcein-labelled WEHIs, a mouse monocytic cell line, or 
isolated blood monocytes (20,000) plus the test factors (rmMIF and anti-MIF mAb) 
were added on top of the layer. After incubation for 16 h, adherent cells were 
analyzed. Different conditions were used for the adhesion assay.  
 
First, I tested whether the assay medium has an influence on the adhesion capacity 
of WEHIS to the endothelial SVEC-layer. Therefore I used minimal medium (RPMI + 
0.5% FBS + 1% penicillin/streptomycin) and BSA medium (RPMI + 0.1% BSA + 1% 
penicillin/streptomycin). Increased fluorescence intensity compared to that of SVECs 
and PBS-containing wells were used to verify the success of the adhesion. I 
observed no significant differences between the two assay media, not even within the 
groups. Only when using BSA medium, a tendency of enhanced adhesion of the 
WEHIs after anti-MIF mAb incubation was found (Figure 27 A). 
 
Next, I checked whether the number of cells makes a difference in the adhesion after 
the differential stimuli. Using more cells (50,000 WEHIs) I observed an increased 
fluorescence signal reflecting a higher level of adherent cells compared to 20,000 
cells. Anti-MIF mAb slightly increased the adhesion in both conditions but did not 
reach statistical significance. rmMIF has no effect (Figure 27 B). 
 
Furthermore, I tested the adhesion of isolated blood monocytes from mice after 
rmMIF and anti-MIF mAb stimulation. I detected no differences after both stimulations 
(Figure 27 C). Considering the data on the adhesion of monocytes, I conclude that 
rmMIF and anti-MIF mAb have no effect after 16 h on the static adhesion capacity of 
monocytes to an endothelial monolayer. 
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Figure 27: Adhesion of monocytes to an endothelial monolayer. Different assay media 
were compared with regard to the adhesion of the monocytic cell line (WEHIs). Neither the 
minimal medium nor the BSA medium affects the adhesion capacity (A). More cells (50,000 
WEHIs) show more fluorescence signal but no differences after different stimuli were 
observed (B). rmMIF and anti-MIF mAb failed to induce altered adhesion of isolated blood 
monocytes compared to control (unstimulated) (C).  
 
 
To test whether the adhesion of WEHIs to an endothelial monolayer under flow 
conditions, representing physiological conditions, differ between rmMIF and anti-MIF 
mAb incubation, I performed flow cell-adhesion experiments. Both treatments induce 
and enhance the adhesion of monocytes (rmMIF 63.55+/-5.55, anti-MIF 84.77+/-6.73 
vs. ctr 41.00+/-8.04, p<0.05) (Figure 28 A). 
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Moreover, I tested the effect of rmMIF and anti-MIF mAb stimulation on the 
transmigration capacity of WEHIs through the filter membrane over an additional 
SVEC-layer. rmMIF decreased the transmigration (rmMIF 10.62+/-0.74 vs. ctr 
21.23+/-2.3). Contrary, anti-MIF mAb showed no difference compared to control 
(anti-MIF 22.80+/-3.0 vs. ctr 21.23+/-2.3), but significantly differs from the rmMIF 
stimuli (anti-MIF 22.80+/-3.0, p<0.05; vs. rmMIF 10.62+/-0.74, p<0.05) (Figure 28 B). 
 
 
 
 
Figure 28: Role of MIF in monocyte recruitment. Both treatments, rmMIF and anti-MIF 
mAb triggered the adhesion of WEHIs to an endothelial monolayer under flow conditions 
(*p<0.05 vs. control) with a significant higher level after anti-MIF mAb treatment (#p<0.05 vs. 
rmMIF). SVEC monolayers were perfused with rmMIF or anti-MIF stimulated WEHIs. Firmly 
adherent monocytes were counted (A). rmMIF lowers the transmigration capacity of WEHIs 
through an endothelial monolayer (*p<0.05 vs. control), whereas after anti-MIF mAb 
treatment no differences were observed compared to control. However, compared to rmMIF, 
anti-MIF mAb treatment doubled the transmigration capacity (#p<0.05) (B).  
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V DISCUSSION 
 
V.1 The Double-edged Role of the CXCL12 / CXCR4 Axis in Experimental 
Myocardial Infarction  
Myocardial infarction caused by the thrombotic occlusion of an atherosclerotic 
coronary artery represents a leading cause of death in western countries. Hence, 
new therapeutic strategies are urgently required to treat myocardial infarction and 
ischemic cardiomyopathy. The CXCR4 receptor ligand CXCL12 has been implicated 
in protection and regeneration after MI through recruiting angiogenic cells, improving 
neovascularization and cardiac function. Here, I evaluated the intrinsic functions of 
CXCR4 in remodeling after MI. 
 
These data demonstrate double-edged effects of CXCR4 on myocardial remodeling 
after MI and point to a variety of possible mechanisms with major clinical implications. 
Compared with wild-type, CXCR4+/- mice revealed smaller and more stable MI scars 
due to an altered post-inflammatory pattern characterized by an attenuation of the 
acute inflammatory recruitment of neutrophils, a shift towards a more regenerative 
monocyte response and better adaptation of cardiomyocytes to hypoxic stress. This 
was paralleled by impaired EPC function, myocardial neovascularization and 
coronary flow recovery, overall amounting in a lack of improvement of ventricular 
function. Given the major efforts to exploit the CXCL12/CXCR4 axis therapeutically to 
promote angiogenesis and cellular regeneration, our data provide important insights 
as to the endogenous function of CXCR4 after MI. 
 
First, I found an altered inflammatory pattern in CXCR4+/- mice after MI characterized 
by diminished myocardial infiltration with neutrophils and tissue-degrading Gr1high 
monocytes and earlier infiltration with Gr1low monocytes, which have been associated 
with deposition of collagen (Nahrendorf et al., 2007). Accordingly, we found that the 
relative collagen content in the smaller MI scars was increased. Neutrophils release 
reactive oxygene species, proteases and express mediators capable of amplifying 
cell recruitment. Hence, a reduced neutrophil infiltration itself represents a self-
sufficient mechanism to impair myocardial injury and reduce infarction size (Eash et 
al., 2009; Tarzami et al., 2003). Recently, CXCR4 has been identified as a central 
regulator of neutrophil homeostasis directing their release from the bone marrow 
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under stress conditions (Eash et al., 2009). Although a complete disruption or 
deficiency of CXCR4 caused an expansion of less mature neutrophils in the 
circulation in the chronic context of atherogenesis (Zernecke et al., 2008b), the group 
of Karshovska found that an acute mobilization of neutrophils induced by severe 
vascular injury was blocked by the potent CXCR4 antagonist AMD3645 (Karshovska 
et al., 2008). Similarly, I observed that MI caused an acute expansion of circulating 
neutrophils and their myocardial recruitment, which was attenuated in CXCR4+/- 
hearts. This is in line with a recent study, which failed to detect neutrophil 
mobilization after various forms of stimulation or Listeria monocytogenes infection, 
when CXCR4 signaling was abrogated (Eash et al., 2009). It seems that there are 
different mechanisms of neutrophil release in normal physiological state and after 
acute stress, which both involved CXCR4, but in a different manner. Thus, these data 
confirm a role of CXCR4 in injury- or stress-induced neutrophil mobilization allowing 
their subsequent recruitment.  
 
Besides neutrophils, monocytes play an important and finely tuned role in cardiac 
repair (Nahrendorf et al., 2007). I found that after MI overall monocyte/macrophage 
infiltration into the myocardium was delayed but enhanced at later stages in 
CXCR4+/- mice. This corresponds to a reduced infiltration with Gr-1high inflammatory 
monocytes, which enter the infarcted myocardium during the initial phase, in a 
process that may be governed by neutrophil secretory products (Liehn et al., 2008). 
Preventing Gr-1high monocytosis results in a delayed or inefficient removal of 
apoptotic cells and necrotic tissue but does not impede the healing (Nahrendorf et 
al., 2007). Conversely, Gr-1low monocytes, which promote healing via myofibroblast 
accumulation and collagen deposition, were more prevalent and recruited earlier after 
MI in CXCR4+/- mice. This shift to a more regenerative response may contribute to 
smaller and stable scar formation. Interestingly, I found that Gr-1high monocytes from 
CXCR4+/- mice did not display reduced CXCR4 expression. Whereas one may 
hypothesize that the regenerative Gr-1low cell subset employs additional receptors to 
compensate for lower CXCR4 levels in recruitment, these data generally imply an 
important role of other receptors, namely CCR2, in the recruitment of Gr-1high 
monocytes. 
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Despite the reduced MI size, the ventricular function was not significantly improved in 
CXCR4+/-mice 4 weeks after MI. This could be due to the reduced basal coronary 
flow and to the impaired coronary flow recovery in CXCR4+/- hearts 4 weeks after MI. 
As an underlying mechanism, we studied the function of EPCs as important 
contributors to neovascularization after MI. The SDF-1/CXCR4 interaction is crucially 
involved in the mobilization and recruitment of stem and progenitor cells to the heart 
after MI (Abbott et al., 2004; Lapidot and Petit, 2002). Ones EPCs arrive at the 
ischemic infarction site, they are able to differentiate and gain endothelial markers. 
Despite appropriate expression of typical endothelial differentiation markers, such as 
uptake of acLDL and Lectin, VE-cadherin, vWF, CD31 or VEGFR2, splenic EPCs 
from CXCR4+/- mice showed deficient chemotaxis towards CXCL12 (but not VEGF) 
and reduced tube formation in vitro. EPCs failed to establish contact with other cells 
and subsequently failed to invade and integrate into the new vessel structures. 
Accordingly, myocardial vessel density, endothelial cell content and arterial branching 
in vivo was impaired in CXCR4+/- mice, indicating a defect in angiogenesis and 
neovascularization after MI. This is in line with a previous study showing that EPCs 
from CXCR4+/- mice were also significantly impaired to restore blood flow in ischemic 
nude mice compared with wild-type EPCs in the hindlimb ischemia model (Walter et 
al., 2005). Showing in vitro that these effects are mostly due to a dysfunction of EPC, 
I cannot exclude that a decrease in the surrounding vascular density also plays a 
supportive role in our in vivo models through reducing the number of circulating cells, 
which are available at the site of injury. Conversely, a lack of functional improvement 
in CXCR4+/- mice cannot be explained by a modulation of cardiomyocyte contractility 
by CXCR4, because CXCL12 has been shown to exert negative inotropic effects 
(weaken the contraction of the heart muscel) (Pyo et al., 2006) so that one would 
rather expect improved ventricular function upon inhibition of deficiency of CXCR4.  
 
Moreover, I performed bone marrow chimera experiments to distinguish the influence 
of the CXCR4 heterozygous background and its effect on circulating cells in normally 
developed wild-type mice. Despite a reconstitution with wild-type bone marrow, a 
reduction of infarction area and neovascularisation persisted in CXCR4+/- mice. 
Moreover, a significant albeit less marked reduction was observed in wild-type mice 
reconstituted with CXCR4+/- bone marrow. This indicates that reduced CXCR4 levels 
on the circulating cells, namely progenitor cells and leukocytes, may also contribute 
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to the effects observed after MI in CXCR4 heterozygous mice, independently of their 
abnormal cardiovascular development. 
 
Notably, the reduced basal and neovascularisation of CXCR4+/- hearts without any 
sign of physiological dysfunction raises several questions. Diminished blood supply 
should lead to a series of histopathological and structural changes of the myocardium 
with an increase in ventricular mass and volume, and progressive decline in left 
ventricular performance. None of these parameters, however, differ in CXCR4+/- mice 
compared with wild-type mice. Hence, I assumed that a protective or adaptive 
mechanism in CXCR4+/- myocardium would ensure cardiac function even under 
reduced oxygen conditions. Indeed, no sign of increased apoptosis was observed. 
After MI, CXCR4+/- myocardium is spared and hypoxic injury seems to be less 
extensive compared with wild-type mice. Using electron microscopy, I observed 
lipofuscin-like lipid accumulations, which resembled those found in rat hearts after 
dietary fish-oil feeding (Nalbone et al., 1988) and may include long-chain 
monounsaturated fatty acids and degraded forms of peroxidized lipids. Although the 
result of a clinical trial using polyunsaturated fatty acids showed only a minimal effect 
on mortality (Svensson et al., 2007; Tavazzi et al., 2008), another study 
demonstrated a diet enriched with unsaturated n-3 fatty acids can reduce ischemic 
damage to the heart (Hock et al., 1990). Higher levels of unsaturated fatty acids 
triglyceride fraction CXCR4+/- hearts may thus represent a possible lead to protection 
but this clearly requires further investigation into underlying mechanisms. 
 
Another notable difference in the lipid extracts of CXCR4+/- myocardium, I detected 
high levels of phosphatidylserine (PS), known as a marker of cell death releasing an 
important destruction signal for macrophages when exposed on the cell surface 
(Hunter et al., 2005). Moreover, PS supports other cell functions, including 
mitochondrial membrane integrity for energy production and activation of protein 
kinase C, which plays an important role in tolerance to hypoxia during late 
preconditioning (Baxter and Ferdinandy, 2001). This has been involved in the 
inhibition of specific immune responses, which may extend to local inflammation 
(Hoffmann et al., 2005). Within this context, specially the PKCε isoform seems to be 
for major importance in cardioprotection from ischemia (Budas and Mochly-Rosen, 
2007). For activation, PKCε requires diacylglycerol (DAG) and PS. Although the 
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protective role of DAG in MI was shown (Baxter et al., 1997), the effect of PS on the 
hypoxic myocardium has not been investigated yet. On the other hand, PS are 
involved in reducing the specific immune response (Hoffmann et al., 2005) and might 
possess ergogenic properties during physical exertion (Kingsley et al., 2005). Since 
the oral administration of PS, which are already commercially available, can speed 
up recovery, prevent muscle soreness, and improve well-being (Kingsley, 2006; 
Kingsley et al., 2006; Kingsley et al., 2005). 
 
In this study, the permanently decreased coronary flow in CXCR4+/- mice may induce 
a chronic ischemia in the heart and thus force cardiomyocytes to adapt even from 
early stages of embryonic development on. An increase in cardiac PS seems to be a 
possible cause mediating this adaptive mechanism, since pre-incubation of 
cardiomyocytes with PS isolated from CXCR4+/- hearts protected cardiomyocytes 
against hypoxic injury. Although the exact mechanism remains to be established, this 
suggests that PS may contribute to the adaptation of CXCR4+/- hearts to reduced 
oxygen supply. 
 
Extensive attempts have been made to directly affect the CXCL12/ CXCR4 axis, e.g. 
by direct injection, nanofiber-mediated delivery of CXCL12 or overexpression of 
CXCL12/ CXCR4 in cells transplanted into the myocardium (Abbott et al., 2004; 
Askari et al., 2003; Hu et al., 2007; Saxena et al., 2008; Schuh et al., 2008; Segers et 
al., 2007; Zhang et al., 2008), aiming to reduce MI size and to improve ventricular 
function after MI. However, endogenous functions of CXCR4 in ischemic cardio-
myopathy and concomitant adaptive processes had not been studied. The double-
edged effects of CXCR4 are illustrated by an alteration of the inflammatory response 
and protection against hypoxic stress, as well as impaired EPC function, 
neovascularization and coronary flow recovery, which overall result in a limitation of 
MI scar size without improved ventricular function. Pharmacological antagonism of 
CXCR4 with AMD3100 has been reported to reduce infarct size and to improve 
ventricular function after MI in rats (Proulx et al., 2007). Whereas the decrease in MI 
size is consistent with the findings in this study, an improved contractility has been 
explained by a suppression of the hypertrophic response in the non-infarct area. This 
differs from CXCR4+/- mice, which have intrinsically reduced coronary flow and can 
be considered as a model for congenitally impaired vascularization and adaptation to 
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hypoxia. Thus, cell-specific, context-dependent and long-term effects of CXCR4 
interference or CXCL12 application need to be carefully taken into account when 
devising therapeutic strategies for MI and ischemic cardiomyopathy. 
 
 
V.2 The Angiogenic Potential of MIF and EPCs 
Cell therapy, especially stem and progenitor cell based therapy including the use of 
EPCs, qualifies as a key to regenerate injured tissue (Lyngbaek et al., 2007; Schuh 
et al., 2008), and therefore is considered one of the greatest hopes in treating 
ischemic diseases (Jain and Duda, 2003). EPCs derived from human blood and 
blood stem cells are of major focus but also cells derived from the bone marrow 
(BMCs) are used for the treatment of acute myocardial infarction.  
 
Stem or progenitor cell therapy provides an opportunity to regenerate functional 
myocardial tissue. During clinical trials BMCs therapy resulted in improvement of 
cardiac performance parameters with reduction of left ventricular dilatation 
(Kuswardhani and Soejitno, 2011). This suggests beneficial effects of BMCs therapy 
for acute myocardial infarction with an increase in cardiac output but also a 
prophylactic effect for late complications like chronic heart failure (Kuswardhani and 
Soejitno, 2011). In the more than 2-years follow-up study “REPAIR-AMI”, a significant 
lower incidence of major adverse cardiovascular events (i.e. death, revascularization, 
reinfarction) was observed for patients with acute myocardial infarction treated with 
autologous BMCs (Assmus et al., 2010).  
 
The peripheral blood of adult humans contains endothelial progenitor cells (EPC). In 
vitro, these cells can differentiate into mature endothelial cells, while in the ischemic 
tissue models these cells contributed to neovasculogenesis (Murohara, 2001). 
Experimental myocardial infarction studies have shown that EPCs injected in the 
ischemic infarct zone migrate to the ischemic region and improve the hemodynamic 
function of the heart (Kawamoto et al., 2001). Unfortunately, the underlying 
mechanism of this therapeutic benefit is not clearly understood. Animal studies 
revealed the cardiomyogenic potential of hematopoietic stem cells and their ability to 
improve neovascularization, reduce fibrosis and support left ventricular function after 
myocardial infarction (Jackson et al., 2001; Kawamoto et al., 2001). Also in clinical 
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studies the potential of EPCs to improve vasculogenesis, angiogenesis and organ 
functions in ischemic diseases was shown (Hill et al., 2003; Schmidt-Lucke et al., 
2005).  
 
Stem cell induced angiogensis, as a process of neovascularization has obtained 
great interest for treating cardiovascular ischemic diseases. Angiogenesis is a highly 
regulated complex morphogenetic process depending on a cocktail of factors and 
involving multiple steps. Chemokines and cytokines are involved in this process, 
improving chemotaxis, transmigration and integration of EPCs and tube formation in 
vitro (Hristov, 2003; Urbich, 2004). Proliferation and migration of endothelial cells 
together with growth factors and chemokines are key regulators in angiogenesis. To 
better understand the behavior of EPCs in response to different growth factors, I 
evaluated the angiogenic potential of different factors; rmMIF, rmVEGF, rmCXCL12 
and rmCXCL1 associated with the function of EPC in angiogenesis.  
 
Endothelial cells belong to one of the few cell types that express receptors that 
specifically bind the acetylated form of LDL (acLDL). Therefore, uptake of AcLDL is 
regarded to plead for an endothelial phenotype. These data indicate that EPCs, 
isolated from mice spleens exhibit endothelial-like properties, namely acLDL uptake, 
binding of lectin, and expression of mononuclear- and endothelial specific markers, 
as well as CXCR2 and CXCR4, receptors for e.g. CXCL1, MIF and CXCL12. Both 
chemokine receptors, CXCR2 and CXCR4 are needed for angiogenesis in vivo 
(Addison et al., 2000; Ma et al., 1998; Tachibana et al., 1998). Mice deficient for 
CXCR4 die perinatally and display profound defects in the development of arteries of 
the gastrointestinal tract, as well as defects in vascular development and in the 
hematopoietic system (Ma et al., 1998; Tachibana et al., 1998). CXCR2 knockout 
mice showed impaired angiogenesis of the cornea in response to CXCR2-ligand-
induced angiogenic activity (Addison et al., 2000).  
 
Mobilization of EPCs and neovascularization mediated by EPCs is strongly regulated. 
The number of circulating EPCs can be increased by mobilizing them from the bone 
marrow by factors such as G-CSF, statins, erythropoietin, VEGF, SDF-1 (CXCL12) or 
NO (Hoenig et al., 2006). Stimulating mobilization can be worthwhile before collecting 
blood for EPC-culture. However, the quality and efficiency of these mobilized EPCs is 
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under debate (Sarkar et al., 2007). Another way to increase the yield of EPCs upon 
cultivation of PBMCs is the addition of factors that stimulate endothelial 
differentiation. Candidates are VEGF, GM-CSF and statins (Dimmeler et al., 2001).  
 
Recruitment and integration of EPCs requires a well coordinated multistep process 
including adhesion, chemoattraction, migration and eventually the differentiation to 
endothelial cells (Hristov, 2003; Urbich, 2004). Here, I showed that EPCs are able to 
integrate into a vascular network of SVECs on matrigel in vitro. A number of growth 
factors and chemokines promote angiogenesis after birth. The best characterized of 
these pro-angiogenic factors is VEGF, which triggers angiogensis both in vitro and in 
vivo by promoting endothelial proliferation, survival and migration (Ferrara et al., 
2003). Here, I demonstrated that rmVEGF, but also rmMIF, rmCXCL12 and 
rmCXCL1 enhanced the chemotactic capacity of EPCs. Chemoattraction and 
transmigration are two distinct processes involved in the development of blood 
vessels. EPCs showed a different transmigration behavior as compared to their 
chemotactic potential. rmMIF and rmCXCL1 enhanced the number of transmigrated 
cells through an endothelial monolayer, whereas rmVEGF and rmCXCL12 failed to 
induce this effect.  
 
When cultured on Matrigel, endothelial cells spontaneously form tubes. Here we 
show that SVECs were able to form tubes in Matrigel in vitro after 24 h. Culturing 
EPCs on Matrigel and determining their ability to form tubes showed that EPCs alone 
are not able to form tube-like structures, distinguishing them from a true endothelial 
phenotype. Nonetheless, the angiogenic potential of EPCs could be proven in co-
culture with SVECs showing a high responsiveness of EPCs to all growth factors 
tested in the initiation of tube formation and integration of EPCs into capillary-line 
tubules displaying pro-angiogenic properties. It is considered that incorporated EPCs 
into newly formed capillaries enhance neovascularization and promote cardiac 
regeneration by releasing pro-angiogenic growth factors such as SDF-1 and VEGF, 
which increase the migration of mature endothelial cells and tissue resident cardiac 
progenitor cells (Urbich et al., 2005). In addition, the increased expression of 
cytokines may improve blood vessel formation after cell therapy (Urbich et al., 2005).  
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Recently, much literature has arisen concerning EPCs, both as a useful stem cell and 
as a biomarker for cardiovascular diseases (Fadini et al., 2008; Schmidt-Lucke et al., 
2005). However, poor standardized specification of EPC characteristics have resulted 
in the use of a diversity of cell population for therapeutics and research. This diversity 
might be directly related to the rather controversial data on EPC isolation, culturing, 
functionality and thus therapeutic efficacy. Despite the fact that my EPCs, cultured 
over 10 days, showed endothelial characteristics I call them in accordance with Hue 
et al. angiogenic early outgrowth cells (Hur et al., 2004). EPCs cultured up to 22 days 
(maximum of 3 passages) upon which they are phenotyped for endothelial 
characteristics are called the late EPCs (Hur et al., 2004) and are by Ingram and 
coworkers regarded to be the true EPCs or endothelial colony-forming cells (ECFCs) 
(Fadini et al., 2008; Ingram, 2004; Yoder et al., 2007). These cells are described to 
be able to have 20-30 population doublings in vitro and thus are able to provide a 
relatively high yield of cells. Long-lasting discussion about EPCs lead to the 
understanding that these cells are present in blood and spleen and should be 
considered a special pro-angionenic subset of monocytes, overlapping in expression 
pattern with endothelial cells (ECs) such as CD34, CD31 and VEGF receptor 2 
(Fadini et al., 2008; Yoder et al., 2007). On the other hand, these cells show 
similarities in endothelial function namely chemotaxis towards VEGF, the capacity to 
form tube-like structures in matrigel and enhancing neovascularization in vivo. 
However, these cells are not able to fully differentiate into endothelial cells, and are 
thus no real endothelial progenitor cells (Fadini et al., 2008; Purhonen et al., 2008). 
Persistent discussions about real EPCs will continue and is of course just a question 
of definition. In fact, the pro-angiogenic function of EPCs remains. However, pro-
angiogenic therapies need to cover multiple steps of angiogenesis including 
stem/progenitor cells and cocktails of involved factors: chemokines, cytokines and 
growth factors. MIF, but also VEGF, CXCL12 and CXCL1 are potential factors to 
increase angiogenesis and might be even more able to promote neovascularization 
in combination with EPCs. Therefore, considering combined treatment of cell-based 
therapies and these factors, combinations of these factors, or optimization of the 
therapeutic angiogenic factor delivery mode gives us the opportunity to manipulate 
and control the pleiotropic nature of angiogenesis. 
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V.3 The Role of Macrophage Migration Inhibitory Factor, a CXCR Ligand in 
Arteriogenesis  
Arteriogenesis is critically regulated by leukocyte functions and alterations of the 
mechanisms of monocyte/macrophage dependent collateral remodeling could affect 
this process. Cytokines like MCP-1, FGF-2, TGF-beta, VEGF, and GM-CSF are 
known to stimulate angiogenesis on one hand and arteriogenesis on the other 
(Buschmann et al., 2003). I showed that the cytokine MIF with chemokine like-
functions known to promote angiogenesis (Amin, 2003; Chesney et al., 1999; Simons 
et al., 2011), negatively influenced arteriogenesis, whereas blocking MIF had a 
positive effect on collateral remodeling. 
 
Accordingly, exogenous MIF reduced the total number of tissue macrophages and 
CXCR2 positive cells present in the ischemic skeletal muscle tissue. The link 
between recruitment of monocytes and, subsequently polarization into tissue resident 
macrophages in the perivascular space of nascent collaterals and remodeling of the 
artery towards a functional conduit has been shown for numerous studies (Arras et 
al., 1998; Heil et al., 2002; Schaper et al., 1976; Scholz et al., 2000). Heil et al. 
showed the functional link between circulating monocyte concentration in the 
peripheral blood and the enhancement of collateral growth (Heil et al., 2002). 
Increasing numbers of CD11b+ monocytes enhanced collateral artery formation and 
blood flow in the impaired regions after acute hindlimb ischemia (Capoccia, 2006; 
Heil et al., 2002). This was accompanied by an increased macrophage accumulation 
in the tissue as demonstrated by immunohistology staining (Heil et al., 2002). Here, I 
demonstrate that blocking MIF raised the circulating CD11b+ monocyte content. 
Additionally, Ly6Chigh monocytes were strongly decreased 24 h after ligation, 
whereas the pro-arteriogenic Ly6Clow monocytes were up-regulated 24 h after ligation 
with an enhanced ability to infiltrate the ischemic muscle observed in a drop of these 
cells after 48 h post-occluded. MIF suppressed CXCR2 expression on macrophages 
in vitro, and hinders monocytes to transmigrate into the tissue.  
 
MIF plays an essential role in the formation of new blood vessel through 
angiogenesis. In mice, the administration of neutralizing anti-MIF antibodies delayed 
the growth of B lymphoma cells and dampened tumor growth, which was 
accompanied by a strong reduction in tumor angiogenesis. Tumor endothelial cells 
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express MIF in vivo, and in vitro, microvascular endothelial cells secrete MIF needed 
for proliferation (Chesney et al., 1999). Similarly, rhMIF induces tube formation in 
Matrigel of human dermal microvascular endothelial cells in vitro and angiogenesis in 
Matrigel plugs and in the corneae bioassay in vivo, further support the pro-angiogenic 
function of MIF (Amin, 2003). 
 
Although angiogenesis and arteriogenesis can be observed after an experimental 
occlusion of a peripheral artery, the relationship between these two modes of 
neovascularization remains undefined. Hypoxia is the principal trigger for 
angiogenesis whereas arteriogenesis is mainly initiated by local changes in shear 
stress as a result of altered pressure gradients along the microvessels that later grow 
out to collaterals (Carmeliet, 2000). On the other hand, most growth factors (e.g. 
VEGF, PDGF, FGF etc. ) that have been studied in detail have pleiotropic effects and 
induce angiogenesis and arteriogenesis (Molin and Post, 2007). Therefore, the 
inhibitory effect of MIF on arteriogenesis is surprising and should be subject of further 
research.  
 
MIF is involved in the inflammatory pathogenesis of atherosclerosis and its 
consequences, e.g. myocardial infarction, ischemia-reperfusion injury, remodeling 
after arterial injury or unstable plaque formation (Zernecke et al., 2008a). In a model 
of wire-induced injury in hypercholesterolemic Apoe-/- mice, blocking MIF resulted in a 
marked reduction of neointimal macrophages and inhibition of transformation of 
macrophages into foam cells contributing to the progression into an unstable plaque 
phenotype (Schober, 2004). The direct participation of MIF in atherosclerotic plaque 
progression was supported in mice studies using MIF-/-Ldlr-/- and Ldlr-/- mice on an 
atherogenic diet (Pan et al., 2004). In MIF-deficient Ldlr-/- mice, abdominal aorta lipid 
deposition and intimal thickening from aortic arch throughout the abdominal aorta 
was reduced compared with Ldlr-/- mice (Pan et al., 2004). Inhibition of MIF leads to 
reduced atherogenesis and the combination of pro-arteriogenesis and anti-
atherogenesis might be of particular therapeutic value. 
 
Monocytes/macrophages likely stimulate arteriogenesis by stimulating migration and 
proliferation of endothelial cells and smooth muscle cells through the production and 
secretion of a cocktail of survival factors, growth factors and cytokines. 
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Monocytes/macrophages are a heterogenous cell population polarized by 
chemokines and cytokines and differ in receptor expression, cytokine profile, and 
chemotactic properties (Gordon and Taylor, 2005). Diverse are the forms of 
macrophage activation and polarization, which can be induced by different 
microenvironmental signals. Macrophage activation could be either pro-inflammatory 
or anti-inflammatory, contributing to tissue destruction or regeneration and wound 
healing (Martinez, 2011). Polarized macrophages have been classified into two 
groups: M1 and M2 macrophages. Classically activated M1 macrophages are 
responsive to inflammatory cytokines such as IFNgamma and microbial products 
such as LPS. Alternatively activated M2 macrophages covers three subsets: M2a 
(induced by IL-4/IL-13), M2b (induced by immune complexes in combination with Il-
1beta or LPS), and M2c (induced by IL-10 and glucocorticoid hormones) (Benoit et 
al., 2008; Martinez et al., 2008). M1 macrophages are part of the Th1 response and 
play a role in tumor resistance and tissue distruction by secreting pro-inflammatory 
mediators and releasing of reactive oxygen and nitrogen intermediates (Benoit et al., 
2008; Mantovani et al., 2009). In contrast, M2 macrophages are diverse but in 
general involved in Th2 response. Furthermore, these anti-inflammatory cells play a 
role in tumor promotion, angiogenesis and tissue remodeling based on the down-
regulation of the pro-inflammatory mediators (Mantovani et al., 2009). In a murine 
hindlimb ischemia model, enhanced arteriogenesis was observed due to an increase 
of tissue-resident M2-like macrophages and their enhanced secretion of arteriogenic 
factors, facilitating smooth muscle cell growth and recruitment (Takeda et al., 2011). 
In this study set up, neither the polarization to M1 nor M2 macrophages was 
observed after rmMIF stimulation indicating that rmMIF does not affect the phenotype 
of tissue resident macrophages. On the other hand, rmMIF reduced the CXCR2 and 
concentration-dependent CXCR4 expression on these cells on mRNA level, which 
might be relevant for further receptor- ligand interactions. Possible interplay of MIF 
and macrophage polarization needs to be further expanded and performed in 
different experimental set ups. 
 
However, blocking endogenous MIF affects the circulating blood monocytes including 
Ly6Clow and Ly6Chigh. Diversity of monocytes is demonstrated by the differential 
expression of surface molecules identifying monocyte subpopulation in human and 
mice. In mice, monocyte subpopulations are distinguished on the basis of the 
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chemokine receptors CCR2 and CX3CR1 and Ly6C (Gr1) antigen expression 
(Geissmann et al., 2003). The CX3CR1low/CCR2high/Gr1high monocytes are recruited 
at sites of inflammation and the CX3CR1high/CCR2low/Gr1low subset characterized by 
CX3CR1-dependent recruitment to noninflamed tissues (Geissmann et al., 2003). 
The pro-angiogenic activity for Ly6Clow monocytes, based on their anti-inflammatory 
profile, tissue repair activities and promoting healing has been proposed, whereas 
Ly6Chigh monocytes produce high levels of inflammatory cytokines and digest 
damages tissue (Arnold et al., 2007; Gordon and Taylor, 2005; Nahrendorf et al., 
2007; Sunderkotter et al., 2004). In a model of murine hindlimb ischaemia, both blood 
Ly6Chigh and Ly6Clow monocyte circulating levels were enhanced after femoral artery 
ligation (Cochain et al., 2010). More specifically, intravenous administration of 
Ly6Clow monocytes are reported to promote arteriogenesis (Cochain et al., 2010) and 
circulate in higher numbers upon blocking MIF, suggesting that endogenous MIF 
keeps these monocytes in check. A similar response is shown for CXCR2 positive 
cells and in fact these cells may in part or even completely overlap the Ly6Clow 
population of monocytes although I currently have no triple labeling data to further 
examine that hypothesis. In arteriogenesis, the relation between monocyte subsets 
(Ly6Clow, Ly6Chigh) and macrophage polarization (M1, M2 macrophages) remains 
unclear. In a mouse myocardial infarction model, GR1low and Gr1high cells have been 
shown to differentiate into M2 and M1 cells, respectively (Nahrendorf et al., 2007). 
However it is still obscure whether this reflects pre-commitment or temporal 
recruitment and exposition to certain environmental signals (Mantovani et al., 2009).  
 
The maximal number of tissue macrophages were observed 2-3 days after occlusion 
contributing to enhanced collateral formation (Scholz et al., 2000). rmMIF significantly 
reduced tissue macrophages in the ischemic skeletal muscle two days after surgery. 
The anti-MIF mAb-induced drop in Ly6Chigh and rise in Ly6Clow population after 24 h, 
with a change in the exactly opposite direction after 48 h after ligation could be the 
result of altered recruitment from the bone marrow or altered migration into the 
vascular wall. Indeed, in our hands, blocking MIF enhances monocyte adhesion 
under physiological flow but not under static conditions. However, monocyte 
migration is not affected by anti-MIF mAb, but reduced after rmMIF treatment. I 
therefore hypothesize that blocking endogenous MIF increases the recruitment of 
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monocytes and specific subsets such as pro-arteriogenic Ly6Clow monocytes as well 
as the immigration into the tissue.  
 
Immunohistochemical stainings for CD74, CXCR4 and MIF and the adhesion of 
monocytes to an endothelial monolayer under flow condition showed positive effects 
after rmMIF and anti-MIF mAb treatment. With regard to the used concentration of 
rmMIF and anti-MIF mAb, which were optimized in preliminary experiments and 
generally in accordance with literature, testing other concentrations for further 
experiments needs to be taken into consideration. Also, it will have to explore why 
both neutralization of MIF and the addition of exogenous rmMIF led to enhanced 
effects under tested conditions. 
 
In conclusion, this study shows that blocking MIF enhanced arteriogenesis likely by 
affecting circulating monocyte subpopulations and subsequent infiltration into the 
tissue surrounding nascent collaterals. Whether rmMIF blocks recruitment of the pro-
arteriogenis Ly6Clow monocytes translating into a reduction of Ly6Clow monocyte 
immigration into collaterals and stimulates recruitment of Ly6Chigh from the 
hematopoietc compartment needs to be further investigated. 
 
The divergent effect of MIF blockade on atherogenesis and arteriogenesis offers 
opportunities for selective therapeutic intervention in peripheral artery disease. 
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VI SUMMARY 
 
The formation of a functional and integrated vascular network is a basic process in 
the growth and maintenance of tissues and can be established by two forms of blood 
vessel growth in adults: angiogenesis and arteriogenesis. In this study, the ligands of 
the chemokine receptor CXCR4 and its role in angiogenesis (represented by the 
experimental myocardial infarction) and arteriogenesis (represented by the murine 
hind limb ischemia model) was investigated.  
 
The first approach identified the CXCL12 / CXCR4 axis in protection and 
regeneration after myocardial infarction associated with complex remodeling and 
inflammatory changes. Experimental MI was induced by ligation of the left 
descending coronary artery in CXCR4+/- and wild-type mice. After four weeks, infarct 
size was reduced in CXCR4+/- compared to wild-type mice. This was accompanied by 
altered inflammatory cell recruitment, namely diminished neutrophil content, delayed 
monocyte infiltration and predominance of Gr1low over classical Gr1high monocytes. 
Basal coronary flow and its recovery after MI were significantly impaired in CXCR4+/- 
mice. This was paralleled by reduced angiogenesis, myocardial vessel density and 
endothelial cell count. Despite defective angiogenesis, CXCR4+/- hearts showed no 
difference in CXCL12, VEGF or apoptosis-related gene expression. Lipofuscin-like 
accumulation in CXCR4+/- hearts and high levels of phosphatidylserine, which protect 
cardiomyocytes from hypoxic stress in vitro were detected. These data showed the 
crucial role of CXCR4 in endogenous remodeling processes after MI, contributing to 
inflammatory/progenitor cell recruitment and neovascularization, whereas its 
deficiency limits infarct size and causes adaptation to hypoxic stress. This should be 
carefully taken into account, when devising therapeutic strategies involving CXCL12 / 
CXCR4 axis.  
 
Chapter 2 provides new insights into the behavior of EPCs in response to angiogenic 
factors: MIF, VEGF, CXCL12 and CXCL1. Spleen derived EPCs exhibit endothelial-
like properties, namely acLDL uptake, binding of lectin, and expression of 
mononuclear- and endothelial specific markers, as well as CXCR2 and CXCR4. 
rmMIF, rmVEGF, rmCXCL12 and rmCXCL1 enhanced the chemotactic capacity of 
EPCs, whereas only rmMIF and rmCXCL1 stimulation increased the number of 
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transmigrated EPCs through an additional endothelial monolayer. Culturing EPCs on 
Matrigel showed that EPCs alone are not able to form tube-like structures, but 
integrate into capillary-line tubules in co-culture with endothelial cells with a high 
responsiveness to all test factors. Therefore, considering combined treatment of cell-
based therapy including EPCs and angiogenic factors might provide new therapeutic 
approaches to regenerate injured tissues.  
 
The third part of this work intended to analyze the role of MIF in arteriogenesis in a 
murine hind limb ischemia model. The pro-inflammatory cytokine with chemokine-like 
functions plays a critical role in inflammatory diseases associated with attracting 
immune cells to sites of inflammation. In mice with femoral artery ligation, paw 
perfusion was diminished after rmMIF stimulation, whereas blocking MIF enhanced 
paw perfusion and therefore collateral formation. Accordingly, exogenous MIF 
reduced the number of tissue macrophages and CXCR2 positive cells in the ischemic 
skeletal muscle whereas blocking endogenous MIF resulted in an increase of 
macrophages. Monocytes likely stimulate arteriogenesis by stimulating migration and 
proliferation of endothelial cells and smooth muscle cells. Within this context M1 
macrophages are considered pro-inflammatory whereas M2 macrophages are pro-
angiogenic. Neither the polarization to M1 nor M2 macrophages was observed after 
rmMIF stimulation indicating that MIF does not affect the phenotype of tissue resident 
macrophages. However, blocking endogenous MIF affects the circulating blood 
monocytes including Ly6Clow and Ly6Chigh. I hypothesize that blocking MIF increases 
the recruitment of monocytes and specific subsets such as Ly6Clow monocytes from 
the bone marrow and the migration into the vessel wall. The divergent effect of MIF 
blockade on atherogenesis and arteriogenesis offers opportunities for selective 
therapeutic intervention in peripheral artery disease. 
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VII ZUSAMMENFASSUNG 
 
Die Bildung eines funktionalen und integrierten Gefäßnetzes ist ein grundlegender 
Prozess während des Wachstums und der Erhaltung von Geweben und kann durch 
zwei Formen des Wachstums von Blutgefäßen im Adulten gezeigt werden: 
Angiogenese und Arteriogenese. In dieser Dissertation wurden die Liganden des 
Chemokinrezeptors CXCR4 und seine Rolle in der Angiogenese (im Mausmodell des 
experimentellen Myokardinfarkts) und Arteriogenese (im Hinterbein Ischämie 
Mausmodell) untersucht.  
 
Im ersten Forschungsansatz wurde die CXCL12 / CXCR4 Achse im Zusammenhang 
mit Schutz und Regeneration nach Myokardinfarkt, der mit komplexen Umbau- und 
entzündlichen Veränderungen einhergeht, identifiziert. Der Myokardinfarkt wurde 
durch die Ligation der linken Koronararterie in CXCR4+/- und Wildtyp-Mäusen 
induziert. Nach vier Wochen war die Infarktgröße in CXCR4+/- im Vergleich zu 
Wildtyp-Mäusen reduziert. Dies ging einher mit veränderter entzündlicher 
Zellrekrutierung, sowie mit einer verminderten Anzahl an Neutrophilen, verzögerter 
Monozyteninfiltration und das Überwiegen von Gr1low über klassische Gr1high 
Monozyten. Der basale Koronarfluss und die Wiederherstellung nach dem Infarkt 
waren in CXCR4+/- Mäusen signifikant beeinträchtigt. Dies wurde begleitet durch 
reduzierte Angiogenese, myokardialer Gefäßdichte und Anzahl an endothelialen 
Zellen. Trotz defekter Angiogenese zeigten CXCR4+/- Herzen keinen Unterschied in 
der Expression von CXCL12, VEGF oder Apoptose-verwandten Genen. 
Lipofuszinartige Ansammlungen in CXCR4+/- Herzen und hohe Anzahl von 
Phosphatidylserinen, die die Kardiomyozyten in vitro vor hypoxischem Stress 
schützen, konnten nachgewiesen werden. Diese Daten zeigen die wichtige Rolle von 
CXCR4 in endogenen Umbauprozessen nach Myokardinfarkt, die bei der 
entzündungsabhängigen Progenitorzellrekrutierung und Gefäßneubildung beitragen, 
während CXCR4 Mangel die Infarktgröße begrenzt und die Anpassung an 
hypoxische Bedingungen bewirkt. Diese Punkte sollten sorgfältig bei der Entwicklung 
neuer Therapeutika berücksichtigt werden, die die CXCL12 / CXCR4 Achse 
involvieren. 
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Das 2. Kapitel liefert neue Einblicke in das Verhalten von EPCs in Reaktion auf 
angiogene Faktoren: MIF, VEGF, CXCL12 und CXCL1. EPCs, die aus der Milz 
isoliert wurden, weisen endothelzell-ähnliche Eigenschaften auf, wie die Aufnahme 
von acLDL, die Bindung von Lektin und die Expression von mononukleären- und 
endothelzell-spezifischen Markern sowie die Expression von CXCR2 und CXCR4. 
rmMIF, rmVEGF, rmCXCL12 und rmCXCL1 verbessern die chemotaktische 
Kapazität von EPCs, während nur rmMIF und rmCXCL1 in der Lage sind weiterhin 
auch die Zahl der transmigrierten EPCs durch einen zusätzlichen endothelialen 
Monolayer zu erhöhen. Die Kultivierung von EPCs auf Matrigel zeigte, dass EPCs 
allein nicht in der Lage sind, tube-artige Strukturen zu bilden, sondern sich nur in Co-
Kultur mit Endothelzellen in diese kapillar-ähnlichen Strukturen integrieren, mit 
erhöhter Intensität nach Stimulierung mit den Testfaktoren. Dadurch könnte die 
kombinierte Behandlung von zellbasierenden Therapien einschließlich der EPCs und 
der angiogenen Faktoren neue therapeutische Ansätze bieten, um verletztes 
Gewebe zu regeneriere. 
 
Der dritte Teil dieser Arbeit sollte die Rolle von MIF während des 
Arteriogeneseprozesses im murinen Hinterbein Ischämie-Modell untersuchen. Das 
pro-inflammatorische Zytokin mit chemokinartigen Funktionen spielt eine 
entscheidende Rolle bei entzündlichen Erkrankungen, wobei MIF Immunzellen zu 
den Entzündungsherden lockt. In Mäusen, in denen die Femoralarterie ligiert wurde, 
wurde eine verringerte Durchblutung der Pfote nach rmMIF Stimulierung gezeigt, 
während das Blockieren von MIF die Durchblutung und somit die Kollateralisierung 
verbesserte. Dementsprechend reduziert auch exogenes MIF die Anzahl an 
Gewebsmakrophagen und CXCR2 positiven Zellen im ischämischen Skelettmuskel, 
während das Blockieren von endogenem MIF zu einem Anstieg an Makrophagen 
führte. Monozyten sind in der Lage, Arteriogenese zu stimulieren, indem sie die 
Migration und Proliferation von Endothelzellen und glatten Muskelzellen stimulieren. 
In diesem Zusammenhang gelten M1 Makrophagen als pro-inflammatorische, 
während M2 Makrophagen als pro-angiogenetische Zellen angesehen werden. 
Weder die Polarisation zu M1 noch zu M2 Makrophagen wurde nach MIF Stimulation 
beobachtet, das darauf hinweist, dass MIF den Phänotyp von Gewebsmakrophagen 
nicht beeinflusst. Allerdings beeinflusst das Blockieren von endogenem MIF die 
zirkulierenden Monozyten im Blut, einschließlich Ly6Clow und Ly6Chigh Monocyten. Ich 
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vermute, dass das Blockieren von MIF zu einer erhöhten Rekrutierung von 
Monozyten und bestimmten Subpopulationen wie Ly6low Monozyten aus dem 
Knochenmark und zu einer erhöhten Migration in die Gefäßwand führt. Die 
unterschiedliche Wirkung von rmMIF und dem Blockieren von MIF bei Arteriosklerose 
und Arteriogenese bietet Möglichkeiten für gezielte therapeutische Interventionen in 
der Behandlung der arteriellen Verschlusskrankheit. 
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